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Aarthi Vijaykumar Maganti 
MECHANISMS OF TRANSCRIPTIONAL REGULATION IN THE MAINTENANCE OF β 
CELL FUNCTION 
  
 The islet β cell is central to the maintenance of glucose homeostasis as the β cell 
is solely responsible for the synthesis of Insulin. Therefore, better understanding of the 
molecular mechanisms governing β cell function is crucial to designing therapies for 
diabetes. Pdx1, the master transcription factor of the β cell, is required for the synthesis 
of proteins that maintain optimal β cell function such as Insulin and glucose transporter 
type 2. Previous studies showed that Pdx1 interacts with the lysine methyltransferase 
Set7/9, relaxing chromatin and increasing transcription. Because Set7/9 also methylates 
non-histone proteins, I hypothesized that Set7/9-mediated methylation of Pdx1 increases 
its transcriptional activity. I showed that recombinant and cellular Pdx1 protein is 
methylated at two lysine residues, Lys123 and Lys131. Lys131 is involved in Set7/9 
mediated augmented transactivation of Pdx1 target genes. Furthermore, β cell-specific 
Set7/9 knockout mice displayed glucose intolerance and impaired insulin secretion, 
accompanied by a reduction in the expression of Pdx1 target genes. Our results indicate 
a previously unappreciated role for Set7/9 in the maintenance of Pdx1 activity and β cell 
function. β cell function is regulated on both the transcriptional and translational levels. β 
cell function is central to the development of type 1 diabetes, a disease wherein the β 
cell is destroyed by immune cells. Although the immune system is considered the 
primary instigator of the disease, recent studies suggest that defective β cells may 
initiate the autoimmune response. I tested the hypothesis that improving β cell function 
would reduce immune infiltration of the islet in the NOD mouse, a mouse model of 
spontaneous type 1 diabetes. Prediabetic NOD mice treated with pioglitazone, a drug 
that improves β cell function, displayed an improvement in β cell function, a reduction in 
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β cell death, accompanied by reductions in β cell autoimmunity, indicating that β cell 
dysfunction assists in the development of type 1 diabetes. Therefore, understanding the 
molecular mechanisms involved in β cell function is essential for the development of 
therapies for diabetes.  
                                       
                                                                 Raghavendra G. Mirmira, MD, PhD, Chair  
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CHAPTER 1: Introduction 
 
1.1 Pancreas Structure and Function  
The pancreas is a glandular organ located under the stomach and connected to 
the duodenum via the pancreatic duct. The main functions of the pancreas include the 
production of digestive enzymes and maintenance of glucose homeostasis. The 
pancreas consists of three cell types: exocrine, endocrine and ductal cells. The exocrine 
portion, constituting 90% of the pancreas, consists of acinar cells that synthesize several 
digestive enzymes, such as proteases, lipases and amylases, which are released along 
with bicarbonate and water (pancreatic juice) through the pancreatic duct, into the small 
intestine. The endocrine pancreas consists of spherical clusters of cells called the Islet of 
Langerhans, which was first described by Paul Langerhans in 1869 (1). The islet 
functions as an endocrine gland, consisting of five hormone secreting cell types – α, β, 
δ, ε and the F/PP cells – which synthesize and secrete, respectively, glucagon, insulin 
somatostatin, ghrelin, and pancreatic polypeptide. The mouse islet consists of a core of 
β cells, surrounded by a mantle containing the α, δ and F/PP cells, whereas, the human 
isle consists of β cells interspersed with α, δ and F/PP cells (2).  
1.2 The role of pancreatic hormones in glucose homeostasis  
Insulin and glucagon have opposing anabolic and catabolic functions that work in 
concert to maintain glucose homeostasis. A fall in glucose levels stimulates the 
pancreatic α cells to secrete glucagon, a 31 amino acid hormone. Glucagon binds to its 
receptor in the liver to promote breakdown of glycogen (the stored form of glucose) and 
gluconeogenesis (3) and inhibit key enzymes in glycolytic processes, thus contributing to 
an increase in blood glucose. Glucagon also promotes lipolysis in the liver and adipose 
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tissue and protein breakdown in the muscle, liberating free fatty acids, ketone bodies 
and amino acids, all of which can act as alternative sources of fuel for cells.  
  After ingestion of food, an increase in blood glucose causes insulin to be 
secreted from the β cells. Insulin signals to other organs in the body, promoting 
consumption or storage of glucose and thus, decreasing blood glucose to normal levels. 
As blood from the pancreas travels directly to the liver via the portal vein, the released 
insulin is first encountered by the liver. In the liver, insulin reduces hepatic glucose 
output, primarily by inhibition of glycogenolysis (4). Insulin promotes protein and lipid 
synthesis, decreasing availability of gluconeogenic precursors and consequently 
decreasing gluconeogenesis. The reduction in blood glucose by insulin is largely 
achieved through its effect on the liver. Insulin also promotes glucose uptake by skeletal 
muscle and adipose tissue, where glucose is utilized for protein and triglyceride 
synthesis respectively (5). Insulin also has other targets, such as the brain, where it has 
been reported to regulate food intake (6,7) and neuroendocrine counter-regulatory 
response to hypoglycemia (8) and the α cell, where it is involved in inhibition of glucagon 
secretion (9,10). 
Insulin is a 51 amino acid peptide that binds to is cognate receptor to initiate a 
cascade of signaling events. The insulin receptor (IR) is a heterotetrameric 
transmembrane tyrosine kinase that consists of two extracellular α chains and two 
transmembrane β chains, linked by disulphide bonds. When Insulin binds to the α 
domain of the IR, a conformational change results in transphosphorylation of the tyrosine 
kinase domain present in the β chain and subsequent phosphorylation of the 
downstream insulin receptor substrates IRS 1-4. In the skeletal muscle and fat, the 
binding of Insulin to the IR activates signaling pathways that result in the localization of 
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the glucose transporter Glut4 to the plasma membrane, and an increase in protein 
synthesis, cell proliferation and differentiation. Insulin is absolutely essential in the 
regulation of glucose homeostasis and maintenance of overall health and therefore, the 
cell that is responsible for the synthesis and secretion of Insulin, the β cell, is central to 
glucose homeostasis.  
1.3  β cell development 
The pancreas, comprised of epithelial cells, is formed by the outgrowth of the 
foregut endoderm into dorsal and ventral pancreatic ‘buds’, followed by fusion of the two 
buds to form a single pancreas at around embryonic day e12.5 in mice. The 
development of the pancreas is initiated by the expression of homeodomain transcription 
factors Pdx1 and Ptf1a. Development of the pancreas involves communication between 
the mesoderm and the foregut endoderm through mesodermally derived signals such as 
TGFβ (transforming growth factor β), BMP (bone morphogenetic protein), RA (retinoic 
acid) and FGF (fibroblast growth factor) (11). These mesodermal signals mediate the 
suppression of endogenous Hedgehog signaling (via Sonic Hedgehog Shh and Indian 
Hedgehog IHH), which triggers the expression of Pdx1 and Ptf1a at e8.5, leading to the 
development of the dorsal and ventral pancreatic bud (12–15). The bud cells present in 
this stage are referred to as multipotent progenitor cells (MPC) and are Pdx1+Ptf1a+. 
Pdx1+ cells, therefore, are the precursor to all pancreatic cell types, including β cells. 
Homozygous deletion of either Pdx1 (13,16) or Ptf1a (14,15) results in pancreatic 
agenesis. Expansion of the MPC pool occurs between e10.5 and e12.5. The size of the 
MPC pool is indicative of the size of the pancreas in adulthood, therefore, 
predetermining the pancreas’s capacity to mount an adequate compensatory response 
to increased insulin demand. Rotation of the gut tube causes the fusion of the dorsal and 
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the ventral pancreas to form a single pancreas, following which differentiation of the bud 
cells into acinar, ductal and endocrine progenitor cells takes place (Figure 1).  
Expression of Ptf1a drives the cells towards acinar cell fate, whereas expression 
of another homeodomain transcription factor, Nkx6.1 drives the cells towards an 
endocrine/ ductal cell lineage (17). The endocrine cells, marked by the expression of two 
transcription factors, Ngn3 and NeuroD1 (18–20), further differentiate into the five 
endocrine cell types (α, β, δ, ε and PP cells). Pdx1 is required for the differentiation of 
the pancreatic progenitor cell into the mature β cell. Other transcription factors, such as 
NeuroD1, Isl1, Nkx6.1 expressed in other cell types during development, eventually 
localize to the mature β cell and maintain the β cell phenotype. Therefore, deletion of 
these transcription factors can have different phenotypes when depending on when they 
are deleted (See Table 1). MafA expression is required in the maintenance of β cell 
identity (21). MafA however, does not crucially affect β cell fate during development, as 
there is no effect of MafA deletion on any of the endocrine cell types (22,23). Therefore, 
MafA is considered a marker of the mature β cell. Interestingly, Pdx1 is required for the 
transcription of most of these transcription factors, reinforcing its importance in the 
developing and mature β cell (24–26).  
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Figure 1. Transcriptional cascade in the developing pancreas. Schematic 
representation of the transcriptional cascade involved during the differentiation of the 
pancreatic progenitor cell into the mature β cell. 
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Table 1: Pancreatic transcription factors  
Transcription  
Factor 
Type Function Pancreatic 
phenotype of 
mutant 
(development) 
Phenotype of 
mutant (adult) 
Pdx1 
(MODY4) 
Homeodomain 
(HD) 
Required for 
growth of 
pancreatic buds, 
maintenance of 
adult β cell 
identity, function 
and adaptation to 
stress.  
Pancreatic 
agenesis(13,16) 
Overt diabetes, 
dramatic 
reduction in 
insulin
+
 cell area, 
diminished Glut2  
expression (27).  
Pdx1+/-: glucose 
intolerance with 
age, increased β 
cell apoptosis(28) 
Nkx6.1 
 
HD Specifies MPCs 
toward an 
endocrine/ductal 
fate(17). 
Required for β 
cell 
differentiation(29) 
Nkx6.1 null mice 
show 85% reduction 
in β cell precursors, 
and a block in β cell 
neogenesis(29) 
Impaired insulin 
biosynthesis and 
secretion, 
reduced Glut2 
expression, 
decreased β cell 
proliferation(30) 
NeuroD1 
(MODY6) 
bHLH Required for 
normal islet 
formation; 
Maintenance of 
the functional, 
glucose 
responsive 
β-cell phenotype  
neonatal diabetes, 
severe reduction in 
β cells, mature islets 
absent. Reduced 
amylase expression 
(31).   
Glucose 
intolerance, 
impaired Insulin 
secretion. 
Increased 
glycolytic 
metabolism (19) 
Isl1 HD Required for 
pancreatic 
epithelial growth 
and endocrine 
differentiation 
(23).  
 
Loss of 
differentiation of 
exocrine tissue and 
islets (32). 
Decreased 
endocrine hormones 
and cells (33).  
 
Impaired Glucose 
tolerance and 
insulin secretion. 
Diminished 
transcription of 
Pdx1, MafA, 
reducing their 
expression (34) 
MafA Basic Leucine 
Zipper 
Required for 
maintenance of 
mature β cells 
No differences in 
endocrine cells or 
glucose 
homeostasis.  
Glucose 
intolerance, 
impaired insulin 
secretion. 
Diminished levels 
of Insulin, 
NeuroD1, Pdx1, 
Glut2(22)(23) 
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1.4  The mature β cell 
The main function of the mature β cell is to respond to increasing glucose levels 
with appropriate insulin secretion in order to maintain glucose homeostasis. As soon as 
the blood glucose concentration increases beyond a certain threshold level, Glut2, a 
glucose channel with low affinity (high Km ca 15-20mM) (35,36) facilitates glucose entry 
into the cell. Within the cell glucose is converted to glucose-6-phosphate by the key 
glucose sensing enzyme Glucokinase, and further metabolized through glycolysis and 
oxidative phosphorylation resulting in the generation of ATP. Glucokinase is a high Km 
enzyme that is only activated when glucose is abundant and plays an important role in 
the modulation of insulin secretion (37). An increased [ATP]/[ADP] ratio in the cell 
causes closure of the ATP-sensitive K+ channel, depolarizing the membrane. The 
resultant change in membrane potential causes the L-type voltage-gated Ca2+ channel to 
open, allowing an influx of Ca2+ into the cell (38), leading to fusion of insulin secretory 
granules with the plasma membrane and the release of insulin from the β cell (Figure 2). 
In rodents, soon after insulin release, insulin stores in the β cell are replenished by 
translation of Ins1/2 mRNA, followed by increased transcription of the Ins1/2 gene (39). 
The translation of Ins1/2 mRNA is a highly regulated process. Preproinsulin, is a 
precursor peptide from which three mature peptides are derived, peptide chains- A, B 
and C. Within the ER, the signal sequence present at the N terminus of the peptide 
destined to become the B chain is cleaved and disulphide bonds are formed within the A 
chain and between the A and B chains. This more mature form, proinsulin, is then 
packed into transport vesicles that move through the cis and trans Golgi network, to form 
proinsulin-containing granules. Within these ‘immature’ granules, proinsulin is cleaved by 
endopeptidases, such as carboxypeptidase E and pro-hormone convertase 1/3, to 
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cleave the C (connecting) peptide from the mature A and B chains. These later granules 
are called ‘mature granules’ and can secrete mature insulin (disulfide bonded A and B 
chains) and the C peptide upon stimulation. Upon stimulation by glucose mediated 
depolarization, fusion of the vesicular VAMP proteins and the plasma membrane 
syntaxin proteins occurs (40), resulting in secretion of insulin and the C peptide. C 
peptide levels, therefore, are often used to measure endogenous insulin secretion.   
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Figure 2. The islet β cell. Glucose enters the β cell through Glut2, and is metabolized 
through glycolysis and Kreb’s cycle, resulting in generation of ATP. An increased 
ATP:ADP ratio results in closure of the ATP-sensitive K+ channel and opening of the 
Voltage gated Ca2+ channel. The resulting influx of Ca2+ triggers the secretion of Insulin.  
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1.5 Transcription in the adult β cell 
Transcription factors such as Pdx1, Nkx6.1, Isl1, and NeuroD1 are expressed in 
pancreatic cells during development and later, their expression is restricted to the 
mature β cell. These transcription factors play very important roles in the maintenance of 
normal β cell function, as is evidenced by the deletion models described in Table 1. Mice 
with a postnatal β cell-specific deletion of Pdx1 show a reduction in β cell area, along 
with impaired insulin secretion and overt diabetes, accompanied by a reduction in Ins1/2 
and Glut2 mRNAs (27)(41). β cell- specific deletion of Nkx6.1 in 7 week-old mice results 
in reduced Glut2 expression, reduced β cell proliferation, and diminished insulin content. 
These mice also show impaired insulin secretion, in part due to a decline in mature 
granules at the plasma membrane and a reduction in Pcx (pyruvate carboxylase) 
transcription, decreasing total cellular ATP levels. Interestingly, Nkx6.1 deletion also 
appears to increase the number of Ngn3+ cells, indicating that Nkx6.1 may help maintain 
β cells in a differentiated state (30)  
NeuroD1 plays an important role in the mature islet and therefore, contributes to 
insulin secretion and glucose homeostasis. NeuroD1 deletion reduces Ins1 expression 
by 50% and disrupts islet architecture. NeuroD1 regulates insulin secretion by facilitating 
stimulus secretion coupling of insulin secretion, modulating the activity of the KATP 
complex, and a few other components of the exocytosis machinery, although the exact 
mechanism is still unclear (19). Interestingly, islets from NeuroD1-βKO mice upregulate 
various glycolytic genes, a marker of neonatal cells, suggesting that NeuroD1 also plays 
a role in maintaining β cell identity (19). As Islet-1 (Isl1) directly activates the 
transcription of Pdx1 and MafA genes, deletion of Isl1 in the mature β cell diminishes 
Pdx1 and MafA levels, reduces insulin content, and impairs insulin secretion (34). MafA, 
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an adult β cell-specific transcription factor, when deleted in the adult mouse, results in 
glucose intolerance and impaired insulin secretion at 3 weeks of age. Since MafA 
regulates cyclin D2, β cell replication is reduced. MafA deletion also leads to disrupted 
islet architecture, decreased insulin content, and a decline in expression of certain 
exocytosis genes. Furthermore, MafA deletion decreases the number of insulin granules 
docked at the plasma membrane in the first phase of insulin secretion (23). Interestingly, 
when only one transcription factor e.g. Pdx1 is deleted, expression levels of other 
transcription factors also decline, indicating that β cell transcription factors appear to 
form an inter-regulatory transcriptional network, further reinforcing β cell identity and 
function. Evidence for the role of transcription factors in maintaining β cell function is 
also provided by several disease models. For example, several models of T2D show 
reduced expression and reduced DNA binding of MafA (42)(43) and Pdx1 (44)(45).    
Since transcription factors play an essential role in maintaining β cell function in 
normal and disease states, understanding the mechanism of transcriptional activation 
could improve therapeutic strategies. Transcription factors bind to the promoter of a 
target gene and regulate the process of transcription. Transcription involves 
communication between transcription factors and the basal transcriptional machinery 
(containing RNA pol II), ultimately culminating in the progression of RNA pol II along the 
coding region of the gene and generation of a mRNA transcript. Transcription of β cell-
specific genes is mediated both through several β cell-specific and ubiquitous 
transcription factors. The insulin promoter contains several cis-regulatory elements, such 
as A, C and E-box elements (Figure 3A). E47 (or Pan1) is another bHLH transcription 
factor  is ubiquitously expressed, forms a heterodimer with NeuroD1/Beta2 and binds to 
the E-box elements to promote transcription initiation. Similarly, several A-box elements 
(5’-TAAT-3’) that bind to the β cell Lim-homeodomain transcription factors such as Isl-1, 
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Lmx1.1, Lmx1.2, and Lmx2 and Pdx1. Out of the 4 or 5 A-box elements, A3 and A4 
appear to show more activity (46). MafA appears to be the only transcription factor that 
binds to the C1-box element (5’-TGCN7GC-3’). Transcription factors can interact with 
each other to further enhance transcriptional activation of the target gene. For example, 
Pdx1 interacts with NeuroD1/E47 to enhance transcription of the insulin minienhancer 
(47). Even though the binding sites of Pdx1 and NeuroD1 on the insulin promoter are 
present at distant locations, interaction between the two transcription factors is facilitated 
by DNA looping (48). MafA has also been shown to interact with both Pdx1 and 
NeuroD1/E47 to promote transactivation of the insulin promoter (49). In addition, Glis3, a 
Krϋppel-like zinc finger transcription factor has been shown to bind to the Glis binding 
site in the insulin promoter and promote transcription of insulin. Moreover, Glis3 also 
interacts with Pdx1, NeuroD1, and MafA to form a complex and enhance the 
transactivation of insulin by about 20-fold (50). Some of the other ubiquitous transcription 
factors involved in the regulation of insulin include Sp1 and Creb (51–53) etc. The 
studies mentioned above determined the role of specific transcription factors using 
transient transfection assays; therefore, the transcriptional function of a protein was not 
assessed in the context of chromatin. Therefore, the conclusions drawn may not be 
indicative of regulation of the endogenous gene. In the following section, I will discuss 
the role of chromatin in gene transcription.  
A. Roles for Co-activators in transcription 
 In eukaryotes, DNA is arranged in the form of chromatin. A unit of chromatin is 
referred to as a nucleosome, containing 147 bp of DNA wrapped around a histone “core” 
octamer comprised of four histones, H2A, H2B, H3 and H4, each in duplicate. The linker 
histone H1 is present at the DNA entry and exit points and aids in nucleosome 
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compaction. Adjacent nucleosomes are separated by ‘linker’ DNA, about 80bp in length, 
which makes the structure of consecutive nucleosomes appear as beads on a string 
(54). The positively charged lysine and arginine residues of the histone bind to the 
negatively charged DNA to form a stable complex . The context of the chromosomes can 
be altered to give two different ‘states’ of chromatin- euchromatin and heterochromatin. 
Euchromatin is associated with regions of DNA being actively transcribed. 
Heterochromatin, by contrast, consists of condensed chromatin, wherein the 
nucleosomes are present in close proximity to one another; these regions are associated 
with inactive or silenced transcription. The N-terminal tails of histones H3 and H2B 
protrude out of the nucleosome core and are therefore amenable to post-translational 
modifications, such as acetylation, methylation, ubiquitination, phosphorylation, and 
SUMOylation, that can facilitate or repress transcription (55).  
A co-activator that has been studied extensively in the context of insulin 
transcription is p300. p300 is a member of the p300/CBP family of proteins and, by virtue 
of its several protein-protein interaction domains, acts as an adaptor protein, enabling 
the assembly of multicomponent transcription complexes. In addition, p300 possesses 
histone acetyltransferase (HAT) activity, acetylating lysine residues of histones, negating 
their cationic interactions with DNA, resulting in relaxed chromatin (56). p300 has been 
shown to enhance NeuroD1-mediated transcription through acetylation of histones and 
acetylation of NeuroD1 itself (57–59). Furthermore, p300 also augments 
Glis3/Pdx1/MafA/NeuroD1- and Pdx1-mediated transcription of the insulin promoter 
through histone acetylation and relaxation of chromatin (50,60). Acetylation is reversible 
and can be removed by a class of enzymes called histone deacetylases (HDACs).  In 
the presence of low glucose, Pdx1 has been shown to interact with HDAC-1 and HDAC-
2, which deacetylate the insulin promoter and inhibit transactivation (61). Therefore, the 
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balance between HAT and HDAC activity can influence the rate of transcription 
occurring at any specific gene. 
Lysine methylation can occur as mono-, di-, or tri-methylation. DNA is 
monomethylated on specific cytosine residues within cytosine/guanidine dinucleotides 
(CpGs). DNA sequences enriched for repetitive CpG clusters are called CpG islands, 
methylation of which is associated with gene repression. DNA methylation, catalyzed by 
de novo DNA methyltransferases (DNMTs) such as DNMT3a/3b or the maintenance 
DNMT1, play important roles in embryogenesis, development, and gene regulation (62). 
Methylation is also found on the lysine and arginine tails of histones. Lysine methylation 
occurs at K4, K9, K27, K36 and K79 of histone H3, and K20 and K59 of histone H4. 
Methylation at H3K4 and H3K79 correlates with active transcription, while methylation at 
K9, K27 and K36 of histone H3 correlates with repressed transcription (63). Methylation 
alters hydrophobicity (not charge) of the lysine/arginine residue, enabling recruitment of 
other proteins to specific sites, resulting in modified chromatin structure and altered 
transcription (64). 
 For example, H3K9 and H3K27 methylation respectively recruits 
Heterochromatin Protein 1 (HP1) and Polycomb proteins, which stabilize the formation of 
heterochromatin (65,66). In yeast, H3K4 methylation results in recruitment of 
chromodomain 1 (Chd1), a component of the histone acetyltransferases SAGA and 
SLIK, and subsequent transcriptional activation (67). In human islets, Pasquali et al. 
showed that active enhancers were occupied by islet-specific transcription factors and 
were also enriched for H3K4 methylation (25). Lysine demethylation is catalyzed by 
demethylases classified either as lysine-specific demethylases (LSDs) or Jumonji C 
domain-containing histone demethylases (JMJCs). During the demethylation reaction, 
LSD and JMJC demethylases use the cofactors flavin adenine dinucleotide (FAD) and α-
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ketoglutarate respectively. LSD-1, a member of the LSD family, can demethylate mono- 
and dimethylated H3K4. In vivo, LSD-1-mediated demethylation can be regulated by 
protein-protein interactions, as LSD-1 in complex with the transcription factor Co-REST, 
demethylates histones present within the nucleosome (68). As both methyltransferases 
(which use S-adenosyl L-methionine or SAM) and demethylases utilize metabolic 
intermediates to carry out their reactions, recent articles suggest that epigenetic 
modulation of chromatin occurs not only during development, but also in response to 
metabolic stimuli within the cell (69,70). Although methyltransferases and demethylases 
are conventionally known to affect histones, recent studies have begun to appreciate the 
fact that methyltransferases also methylate a host of non-histone proteins, regulating 
transcription through alternate mechanisms (71).  
B. Pancreatic Duodenal Homeobox-1  
 Pancreatic Duodenal Homeobox-1 (Pdx1) is the master transcription factor of the 
β cell. Although Pdx1 is robustly expressed in all pancreatic cells during development, in 
the mature islet, Pdx1 is mainly expressed in β and δ cells. Pdx1 contributes to the 
maintenance of β cell identity, promotes β cell survival and proliferation and adaptation 
to stresses such as endoplasmic reticulum (ER) stress. Pdx1 is essential for the 
expression of β cell-specific genes such as Ins1/2 (72), Slc2a2 (the glucose transporter) 
(73), Gck (the glucose sensing enzyme) (74), MafA (75) and Pdx1 itself (76), indicating 
that Pdx1 is important for the maintenance of β cell identity (27,41). Gao T et al. showed 
that Pdx1 maintains β cell identity, in part, through repression of MafB, a transcription 
factor that is expressed only in postnatal α cells (77). Furthermore, Pdx1 overexpression 
in α cells results in their conversion to β cells (78), emphasizing the role of Pdx1 in the 
maintenance of the adult β cell phenotype. Pdx1 also plays a role in β cell the 
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proliferative that occurs in response to insulin resistance. Mice that are heterozygous for 
Pdx1 and doubly heterozygous for IRS/IR and liver-specific IR knockout mice show an 
abrogation of β cell compensatory hyperplasia and increased β cell death (79). The 
decreased proliferation observed in these mice was attributed to reduced nuclear 
localization of β-catenin, suggesting that Pdx1 could influence cellular proliferation via β-
catenin. (79). Moreover, recent studies have demonstrated that islets isolated from Pdx1 
heterozygous mice fed on a high fat diet displayed distended ER, a hallmark of ER 
stress, and increased expression in markers of the unfolded protein response (UPR), the 
cell’s adaptive response to ER stress. Interestingly, Pdx1 activates the transcription of 
UPR signaling proteins that are required to resolve ER stress, such as Atf4, Wfs1 and 
Ero1β. Therefore, Pdx1 deficiency contributes to unresolved ER stress and β cell death 
(80,81) (explained in more detail in later sections). Pdx1 also regulates the transcription 
of mitochondrial transcription factor A, TFAM. TFAM is a transcription factor that is 
involved in transcription of several mitochondrial DNA (mtDNA) genes including nd1, a 
subunit of the NADH complex I of the mitochondrial respiratory chain.  Hence, Pdx1 
indirectly regulates mtDNA copy number, ATP synthesis and insulin secretion (82). 
Therefore, Pdx1, through transcription of its downstream targets, is central to β cell 
fuction. Not surprisingly, a ChIP-seq study conducted in mouse and human islets 
revealed that 2824 common genes occupied by Pdx1 associated with endocrine and 
metabolic disorders, cell survival, and other signaling pathways (83). This study 
confirmed that we still have only rudimentary knowledge about the downstream targets 
of Pdx1 and more studies need to be performed to determine its transcriptional network.  
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C. Regulation of Pdx1 function 
The Pdx1 gene encodes a 283 amino acid, homeodomain transcription factor  
containing an N-terminal transactivation domain, a DNA-binding homeodomain, and a C-
terminal domain (84). The N-terminal region of Pdx1 acts as a transactivation domain, 
and also interacts with NeuroD1/E47, p300, MafA, and Glis3, as mentioned previously. 
The Pdx1 amino terminus also interacts with Set7/9, a lysine methyltransferase, (85) and 
the PDZ domain coactivator Bridge1 to synergistically transactivate the insulin promoter 
(Figure 3B) (86). The amino terminus contains the highly conserved pentapeptide 
FPWMK, which is the site of interaction between Pdx1 and the ubiquitous homeodomain 
transcription factor Pbx1. Pdx1 and Pbx1 co-operatively transactivate elastase (87) and 
somatostatin (88). Mutated FPWMK pentapeptide disrupts Pdx1:Pbx interaction resulting 
in a dramatic reduction in pancreatic cell proliferation and death in 3 week-old mice (89). 
Furthermore, Pbx1 null mice displayed pancreatic hypoplasia along with a reduction in 
pancreatic differentiation markers such as Isl1, supporting the role of Pbx1 during 
pancreatic development. Pdx1/Pbx1 transheterozygous mice were more glucose 
intolerant than Pdx1 or Pbx1 heterozygous mice and had impaired insulin secretion, 
indicating that the Pdx1:Pbx interaction is important to the mature β cell (90).  
The Pdx1 homeodomain, flanked by proline-rich regions on either side, is lysine 
rich and has strong DNA binding activity toward the TA-rich sequences 5’-TAAT-3’ and 
5’-TGATNNAT-3’ (83). This binding specificity is determined by sequences flanking the 
5’-TAAT-3’ sequence (91). The homeodomain also contains a highly conserved histidine 
at amino acid 189 and a conserved motif KIWFQN that are both important for DNA 
binding (92), in addition to the nuclear localization sequence RRMKWKK (93,94) (Figure 
3C). Kim et al. reported that the retinoblastoma protein pRb interacts with the 
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homeodomain of Pdx1 to regulate its stability. pRb-null embryos display a reduction in 
Pdx1 protein and Pdx1 target gene expression, along with pancreatic hypoplasia and 
increased cell death, indicating an important role for the pRb:Pdx1 interaction during 
development (95). The C terminal region of Pdx1 has also been shown to interact with 
Pcif1 and an E3 ubiquitin ligase that modulates Pdx1 stability (80). As Pdx1 is key to β 
cell development and mature β cell function, it is quite likely that Pdx1 interaction is 
regulated temporally and can vary, depending on the physiological context. 
D. Post-translational modifications of Pdx1 
Apart from protein-protein interactions, Pdx1 protein levels and function are 
regulated by post-translational modifications. Pdx1 has been reported to be 
phosphorylated in several studies, albeit with slightly contradictory results (Figure 3C). 
Humphrey et al. showed that Pdx1 is phosphorylated at Ser 268 and Ser 272 in isolated 
rat islets, in low glucose, by glycogen synthase kinase 3β (GSK3β), resulting in Pdx1 
degradation. When the cells were stimulated with glucose or insulin, Akt and PASK (96) 
phosphorylated GSK3β at Ser 9, inactivating GSK3β and increasing Pdx1 protein levels 
(97). However, homeodomain interacting protein kinase 2 (HIPK2) phosphorylates Pdx1 
at Ser 269 in mice (the same as Ser268 in rats), affecting its localization within the 
nucleus, but not stability (98). Under basal conditions, GSK3β also appears to 
phosphorylate Pdx1 at Ser 61 and Ser 66 within its amino terminus, causing its 
association with ubiquitin ligase and subsequent degradation (99,100). In response to 
radiation, DNA- dependent protein kinase (DNA-PK) phosphorylates Pdx1 at Thr 11, 
resulting in Pdx1 degradation (101). Previous studies have raised the possibility that 
Pdx1 phosphorylation occurs in a PI3K- and p38-dependent manner to increase its 
nuclear localization and transcriptional activity (102,103), however, no residues were 
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identified. On the contrary, Meng et al. found that casein kinase 2 (CK2) phosphorylates 
Pdx1 at Thr 231 and Ser 232, leading to a decrease in transcriptional activity (104). 
Clearly, Pdx1 phosphorylation has context-dependent effects, and its impact on β cell 
function is nuanced. Pdx1 has been shown to be sumoylated, in the absence of which 
Pdx1 is localized to the cytoplasm and degraded (105). Lastly, Pdx1 is also glycosylated 
in response to glucose, resulting in increased DNA binding activity (106) and increased 
free fatty acid receptor 1 (FFA-1/GPR40) gene transcription (107), both of which 
augment insulin transcription and insulin secretion. Since Pdx1 expression and activity is 
often used as a barometer of β cell health, studying its interactions and post-translational 
modifications can provide an important gateway into therapeutic options. 
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Figure 3. Pdx1 structure and function. (A) Schematic representation of the proximal 
region of the rat insulin II promoter showing the key elements and trans-activating 
factors involved in glucose regulation of insulin gene transcription. (B) Pdx1 interacts 
with several cofactors – Bridge1, Set7/9 and p300 increase; HDAC decreases Pdx1 
transactivation on the insulin promoter. (C) Schematic representation of the Pdx1 protein 
depicting the amino terminus (N term), homeodomain (HD) and the carboxyl terminus (C 
term). The purple regions highlighted within the homeodomain denote the DNA 
specificity sequence KIWFQN and the nuclear localization sequence (NLS) RRMKWKK. 
Residues that are phosphorylated are highlighted in red and black. Red residues are 
associated with stability and black residues are associated Pdx1 transcriptional activity. 
Apart from phosphorylation, Pdx1 is also glycosylated and sumoylated.   
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E. Set7/9 
Set7/9, also known as Set7 or Set9 was named based on the presence of an 
evolutionary conserved ‘SET’ (Su(var)3-9, Enhancer of Zeste, Trithorax) domain. The 
Setd7 gene is present on chromosome 4 in humans and chromosome 3 in mice, and 
contains 8 exons that code for a 366 amino acid protein (108). Set7/9 was purified and 
identified as a histone methyltransferase that methylates H3K4. Although Set7/9 
methyltransferase activity is carried out by the SET domain and its flanking residues, 
Set7/9, unlike other methyltransferases, lacks a cysteine-rich pre- and post-SET domain 
(108). Set7/9-mediated H3K4 methylation has been shown to inhibit H3K9 methylation 
by SUV39H1, subsequently permitting p300-mediated H3 acetylation. H3K4 methylation 
also inhibits interaction with the NuRD deacetylase complex and hence, increases 
transcriptional activity (108,109). Set7/9 null mice are 50% embryonic lethal (110). 
Interestingly, Set7/9 does not methylate histones in the context of a nucleosome in vitro: 
the implications of this finding in vivo is unclear, since it is possible that the nuclear 
protein milieu may facilitate histone methylation.  
The role of Set7/9 in non-histone protein methylation has been a popular topic of 
investigation in the last few years. Multiple molecular mechanisms may be affected by 
lysine methylation of non-histone proteins, as exemplified by the following examples. 
Set7/9 methylates TBP associated factor 10 (TAF 10) and increases its affinity for RNA 
polymerase II, thereby, affecting the preinitiation complex and resulting in augmentation 
of transcription of selective target genes (111). Several studies have reported 
monomethylation of the tumor suppressor gene p53 by Set7/9 at residue K372, during 
genotoxic stress (112). Methylation of p53 facilitates acetylation of p53 by Tip60 and a 
subsequent increase in p53 stability and transactivation of its downstream target gene 
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p21 (110), although this study has also been contradicted (113). Transcriptional 
activation of p21 also occurs due to acetylation of H4 within the p21 promoter, which 
follows methylation and acetylation of p53 (114). Therefore, p53 methylation induces cell 
cycle arrest and prevents cellular transformation. The p65 subunit of NF-κB is also 
methylated by Set7/9 at residues K314 and K315, resulting in degradation of DNA-
bound NF-κB and a subsequent decrease in transcription of NF-κB target genes (115). 
Interestingly, p65 methylation at K37 by Set7/9 associates with increased DNA binding 
affinity of p65 and augments transcription of downstream target genes such as TNFα 
(116). These contrasting results hint at the possibility that differential methylation could 
be due to the presence of interacting proteins that could influence Set7/9-mediated 
methylation. Clearly, Set7/9-mediated methylation can affect various aspects of protein 
function, including stability, DNA binding, transcriptional activation, and protein 
interactions (see Table 2). Moreover, Set7/9-mediated protein methylation has been 
shown to be reversible by LSD-1 in certain proteins, such as p53 (117), DNMT1 (118), 
and HIV Tat protein (119).  Hence, protein methylation provides an alternative level of 
dynamic regulation of protein function. 
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Table 2: Protein methylation mediated by Set7/9 
Substrate Lysine Residue Function 
P53 K372;  
K369 in mouse (me1) 
Increase in transactivation of p21, increased 
p53 stability(112), facilitate p53 
acetylation(110,114) 
TAF10 K189 (me1) Enhanced affinity to RNA polymerase II, 
increased transcription of selective target 
genes(111) 
NF-κB (p65 
subunit) 
K314, K315 (me1) 
 
K37 (me1)                           
In response to TNFα, only DNA bound NF-κB is 
methylated and degraded. Decreased protein 
stability. Reduced IL-6 and Nos2 
transcription(115) 
In response to TNFα and IL-1β, methylation 
enhances NF-κB DNA binding and coactivator 
recruitment, increases transcription of subset of 
target genes(116) 
Estrogen Receptor 
(ERα) 
302 (me1) Increased protein stability, Increased 
recruitment of ERα and transcription of target 
genes (120). 
Androgen receptor 
(ARα) 
630 and/or 632 (me1) Increased transactivation of target genes. 
Set7/9 and AR occupancy of target genes was 
associated with increased H3K4 methylation 
and p300/CBP recruitment to the promoter 
(121,122) 
FXR 206 Increased transactivation of target genes by 
increased DNA binding (123) 
Tat protein (HIV) 51 (me1) Stimulation of HIV transcription(124), 
Monomethylation is followed by acetylation; 
transcription also enhanced by LSD-1(119). 
SUV39H1 105, 123 Down regulation of H3K9 methlyation, 
heterochromatin relaxation (125) 
Dnmt1 K1096 Methylation decreases stability and results in 
global DNA hypomethylation. LSD1 
demethylation enhances Dnmt1 stability(118) 
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F. Pdx1-Set7/9 interaction  
Previous studies from our laboratory have focused on the transcriptional ability of 
Pdx1 in the context of chromatin. Chakrabarti et al. showed that by combining EMSA 
and ChIP assays in β and non-β cell lines transfected with the Ins1/2 promoter and 
Pdx1, Pdx1 binding and occupancy was higher in β cells, as the chromatin in Pdx1 
target genes were more open in β cells compared to non- β cells (126). This finding 
raises the possibility that chromatin context may restrict Pdx1 binding to some 
promoters. An increase in the transcription of the Insulin promoter associates with 
increased H3 acetylation, mediated by p300, and H3K4 methylation, mediated by Set7/9 
(126,127). Tail vein injection of Setd7 siRNA resulted in inhibition of Set7/9 in the 
pancreas and a subsequent reduction in Pdx1 target genes Ins1/2, Slc2a2 and MafA, 
coupled with defects in Ca2+ influx and subsequent diminished insulin secretion (128). 
Moreover, α to β cell conversion was associated with nuclear localization of Set7/9, 
suggesting that Pdx1-Set7/9 co-localization is associated with the maintenance of β cell 
identity (78). Pdx1 directly regulates Set7/9 promoter and expression (128,129), which 
eventually augments transcription of other Pdx1 target genes. A study performed by 
Francis et al. (85) revealed a possible mechanism underlying Set7/9-mediated increase 
in Pdx1 target gene expression, showing that Set7/9 was recruited by Pdx1 to the Insulin 
promoter, which underwent H3K4 dimethylation, to increase transcription of the Insulin 
gene. Histone methylation is also associated with conversion of the initiation form of 
RNA polymerase II (marked by Ser-5-P residue in the carboxyl terminal domain, CTD) to 
its elongation form (marked by Ser-2-P residue in the CTD), advancing RNA pol II along 
the coding gene (85). Interestingly, an in vitro transcription reaction performed on a 
chromatinized insulin mini-enhancer template revealed two findings: 1) Pdx1 was 
required for the occurrence of histone methylation and 2) Pdx1 itself was methylated 
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(85). This finding and the literature cited above led us to hypothesize that methylation of 
Pdx1 by Set7/9 enhances Pdx1 transcriptional activity and promotes β cell function.  
1.6 β cell  dysfunction 
Since the β cell is so crucial for glucose homeostasis, maintenance of normal β cell 
function is essential. However, in the presence of several stresses, such as ER stress, 
oxidative stress and inflammation, β cell function is impaired and results in the 
development of disease. Therefore, it is important to understand the mechanisms 
underlying β cell dysfunction.  
A. ER stress in the β cell 
The β cell is a secretory cell. The entry of proteins into the secretory apparatus, 
the Golgi network, is through the endoplasmic reticulum. Within the ER, folding of the 
translated protein is aided by molecular chaperones such as binding Ig protein (Bip), 
oxidoreductases, and protein isomerases that assist in formation of disulphide bonds. 
Furthermore, proteins can accumulate post-translational modifications such as 
glycosylation, which might prevent protein unfolding/misfolding. The endoplasmic 
reticulum of the β cell translates around 1 million insulin molecules per minute (130). 
Also, insulin biosynthesis accounts for 0.4% of the total pancreatic protein synthesized, 
even though islets make up only 1-2% of the pancreas (131). Furthermore, the ER of the 
β cell is acutely sensitive to external stimuli (such as nutrients), and is responsible for 
elevating insulin synthesis accordingly. Moreover, protein translation in the β cell is 
regulated by glucose and free fatty acids (132,133). Quality control in the ER is 
maintained by the degradation of unfolded proteins either through ERAD (endoplasmic 
reticulum assisted degradation), where the proteins are ubiquitylated (134–136) and 
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degraded in the proteasome or through autophagy (137,138). However, insulin 
resistance, hyperglycemia, or inflammation can trigger a sudden increase in protein 
synthesis, which in turn could result in the accumulation of unfolded protein, leading to 
ER stress. ER stress is often associated with a distended ER network, as visualized by 
electron microscopy. ER stress results in activation of the unfolded protein response 
(UPR), which is the cell’s attempt to resolve/adapt to the ER stress and maintain cell 
function. However, if the UPR program of the cell is unsuccessful, UPR signaling instead 
diverts the cell towards apoptosis.   
The UPR pathway has three main arms that are mediated by: Perk (Protein 
kinase RNA (PKR)-like ER Kinase), Ire1α (Inositol Requiring Enzyme 1) and Atf6 
(activating transcription factor 6). These three proteins are transmembrane proteins, 
containing a cytoplasmic and an ER portion, to which the molecular chaperone Bip is 
bound. Unfolded protein induces release of Bip from the three arms (139) or direct 
interaction of unfolded proteins with Perk/Ire1α/Atf6 results in their activation (140). Perk 
is activated by dimerization and trans-autophosphorylation of the kinases, leading to 
phosphorylation of eukaryotic initiation factor 2 α (eIF2α), a protein that mediates the 
initiation of translation (Figure 4). Phosphorylated eIF2α inhibits global mRNA 
translation, but allows translation of only those proteins that are involved in the unfolded 
protein response (UPR) (141). The activation of the Perk arm of the UPR results in 
increased translation (142) of Atf4 (activating transcription factor 4) mRNA, which 
localizes to the nucleus and activates transcription of target genes, such as the pro-
apoptotic protein Chop (143,144), molecular chaperones, and genes involved in amino 
acid biosynthesis and anti-oxidant response, therefore enhancing the protein folding 
capacity of the cell. Patients with mutations in the gene coding for Perk (called Wolcott 
Rallison syndrome) are born with permanent insulin-dependent diabetes, osteopenia, 
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and mental retardation (145). Mutant mice have irremediable ER stress along with 
distended ER and gradual death of β cells, followed by loss of α cells and exocrine 
insufficiency (146).  
Ire1α, a kinase receptor with endoribonuclease activity, is activated in response 
to ER stress in a manner similar to Perk. Ire1α mediates the splicing of several mRNA 
present in the ER, including X-box protein 1 (Xbp1) mRNA and Insulin mRNA (147). 
Spliced Xbp1 (sXbp1) mRNA codes for Xbp1 protein, a transcription factor that together 
with Atf6α, mediates the transcription of molecular chaperones, genes involved in lipid 
biosynthesis and ER and Golgi biogenesis, to expand the ER and enhance the ability of 
the cell to resolve ER stress. The Ire1α-Xbp1 pathway enhances transcription of proteins 
involved in ERAD, such as Edem, ErDj4 and Protein disulfide isomerase (148). The 
Ire1α-Xbp1 arm facilitates the regulation of proinsulin synthesis and insulin secretion 
under transient high glucose conditions in a normal β cell (149,150).  
The third arm of the UPR is Atf6, a basic leucine zipper transcription factor. 
During ER stress, the disulfide bonds of the ATF6 dimer are reduced to release Atf6 
monomers, which relocate to the Golgi. In the Golgi, Atf6 is cleaved by the proteases 
S1P and S2P, to give the nuclear fragment, Atf6n, which localizes to the nucleus and 
mediates transcription of its target genes, including Xbp1 and Chop.  
Sustained ER stress results in the induction of cell apoptosis. ChoP, a bZip 
transcription factor, inhibits transcription of (186) anti-apoptotic Bcl2 proteins (151) and 
induces pro-apoptotic proteins such as the negative feedback inhibitor of eIF2α 
phosphorylation, Gadd34 (152), the Akt inhibitor, Trb3 (153) to promote cell apoptosis.  
During chronic ER stress, interaction between Atf4 and Chop promotes transcription of 
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genes involved in protein synthesis, depleting cellular ATP, inhibiting transcription of 
antioxidant genes, worsening ER stress, and increasing ROS and cell death (154). 
Although, the Chop-/- mice exhibit no differences in their phenotype under normal 
conditions, deletion of Chop in models of type 2 diabetes resulted in improved glucose 
tolerance, β cell function and reduced cell death (155). The Ire1α-Xbp1 pathway also 
mediates apoptosis during irremediable UPR. In the presence of cytokines, Xbp1 can 
increase activation of NFκB, resulting in increased β cell death (156). Ire1α interacts with 
Traf2 (TNFα receptor associated factor), an adaptor protein that facilitates cell apoptosis 
through: 1) recruitment of Ask1 (157) followed by phosphorylation of JNK (158); 2) 
activation of caspase-12 (159); 3) interaction of the pro-apoptotic proteins Bax and Bak 
with Ire1α at the ER membrane, followed by induction of apoptosis (160) and; 4) 
Increasing the release of ER Ca2+, such that the Ca2+ concentration in the mitochondria 
increases, resulting in membrane depolarization, cytochrome C release and apoptosis.   
Apart from the three main arms of the UPR, the sarcoplasmic reticulum calcium 
transport ATPase  2b (Serca2B) in the β cell regulates Ca2+ homeostasis in the ER, that, 
when perturbed, can cause ER stress since protein folding by chaperones is Ca2+ 
dependent (161). In fact, thapsigargin, a chemical inhibitor of Serca2b, is often used to 
induce ER stress in cell-line based studies. Wfs1, a transmembrane protein, aids in 
protein assembly, ERAD (162) and insulin secretion (163)  and negatively regulates 
ATF6 (162). However, in the presence of ER stress, diminished Wfs1 levels can reduce 
insulin secretion (163). β cell-specific deletion of Wfs1 results in the onset of glucose 
intolerance at the age of 12 weeks, contributing to ER stress (164). Clearly, an efficient 
UPR response is crucial to β cell survival.  
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ER stress, inflammation, and oxidative stress are interlinked, with each process 
augmenting one another (133,165). Thioredoxin (Trx), a 12KDa ubiquitous protein that 
possesses disulfide-reducing activity, has two isoforms, Trx1, present in the cytosol, and 
Trx2, present in the mitochondria. Trx activity is induced by UV radiation, viral infection, 
ischemia, etc. In the process of reducing other substrate proteins (for example, insulin), 
disulfide bonds of Trx1 protein itself get oxidized. Thioredoxin reductase helps restore 
oxidized Trx to its reduced form. Therefore, Trx is important in maintaining the redox 
status of a cell. TXNIP (thioredoxin-interacting protein) is a protein that interacts with 
Trx1 in the cytosol and Trx2 in the mitochondria. TXNIP interacts only with the reduced 
form of Trx to inhibit Trx activity. TXNIP has an arrestin-like domain that interacts with 
several proteins such as importin α (166), E3 ubiquitin ligase Mybbp1a (167), and NOD-
like receptor protein 3 (NLRP3) (168). Activation of TXNIP is sensitive to external signals 
and can occur in response to oxidative stress, inflammation, obesity and hyperglycemia. 
TXNIP has been implicated in both type 1 and type 2 diabetes (reviewed in (169)). 
TXNIP may also be an important intermediate between ER stress and inflammation. 
TXNIP is activated by IRE1α and the PERK arms of the UPR, resulting in activation of 
the NLRP3 inflammasome, which produces mature IL-1β, which increases cell death 
(170,171). More studies need to be conducted to determine the other intermediates 
between ER stress, oxidative stress and inflammation, so as to design more effective 
therapeutic strategies to prevent cell death. 
Several attempts have been made to ameliorate ER stress. The activation of 
PPARγ with Pioglitazone, a thiazolidinedione (TZD), has shown promising effects. 
Evans-Molina et al. reported that in INS1 832/13 cells treated with thapsigargin, an 
inducer of ER stress, pioglitazone treatment showed a dramatic reduction in ER stress 
markers. Moreover, db/db mice, a type 2 diabetic mouse model that exhibits ER stress, 
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when treated with pioglitazone, showed improved glucose tolerance, insulin sensitivity, 
and insulin secretion, accompanied by a reduction in islet ER stress. (172). In response 
to pioglitazone treatment, PPARγ binds to its PPRE in the promoter of Serca2b to induce 
Serca2b expression and reduce β cell death (173). Wfs1 knockout mice, when crossed 
with C57BL6 mice, have mild obesity and insulin resistance and showed β cell ER stress 
and apoptosis. Treatment with pioglitazone protected these mice from ER stress and β 
cell death, further supporting the role of pioglitazone in remediating ER stress (174). 
PPARγ activation also transcriptionally activates Pdx1 (172,175), which in turn, acts as a 
transcriptional activator of UPR mediators Atf4, Wfs1 (45) and ER Ca2+ homeostasis 
(176) and helps in augmenting the UPR response and reducing ER stress. PPARγ 
activation was also shown to reduce oxidative stress-induced β cell death in 
pioglitazone-treated db/db mice, with activation of antioxidant gene expression and an 
increase in insulin secretion (177). Hence, pioglitazone treatment can ameliorate β cell 
function and reduce β cell death, through different mechanisms.  
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Figure 4. The Unfolded Protein Response (UPR). In response to unfolded protein, Bip 
(Green Circles), bound to Atf6, Ire1α and Perk is released and aids in protein folding. 
The release of Bip causes dimerization and trans-autophosphorylation (Purple circles) of 
Ire1α and Perk. Phosphorylated Perk phosphorylates eIF2α, inhibiting global mRNA 
translation.  Perk also activates Atf4 and Chop, Ire1α splices Xbp1 mRNA, resulting in 
downstream effects. Atf6 is processed in the golgi (cleavage by S1P, S2P proteases) to 
nuclear Atf6, which acts as a transcription factor for Xbp1 and Chop.  Downstream 
effects labeled in black denote processes that aim to resolve ER stress. Downstream 
effects labeled in red denote processes occurring during chronic stress that induce cell 
death.   
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B. β cell dysfunction in disease 
Deficiency of insulin/insulin signaling leads to the development of diabetes.  Diabetes 
mellitus is a group of diseases characterized by chronically elevated blood glucose 
(>120mg/dl blood glucose). Currently, around 300 million people suffer from diabetes 
(CDC) and according to current trends, around one in three people in the USA, are 
projected to develop diabetes by 2050 (ADA). Complications of uncontrolled 
hyperglycemia include retinopathy, coronary heart disease, nephropathy, 
cerebrovascular disease and poor blood flow to the extremities (diabetic foot). There are 
several forms of diabetes: Type 1 Diabetes (T1D), Type 2 Diabetes (T2D) and MODY 
among others.  
Type 1 Diabetes: This form of diabetes is characterized by immune attack of islet 
β cells, resulting in β cell destruction and hyperglycemia. T1D is diagnosed when low 
serum levels of insulin are observed together with the presence of autoantibodies 
against β cell proteins such as Insulin, GAD-65 (Glutamic acid decarboxylase 65), and 
IA2 (Islet antigen 2) in the serum or plasma of the patient. T1D usually occurs early in 
life, below 18 years of age and is also called juvenile diabetes. However, T1D can also 
occur later in life, in a form referred to as latent autoimmune diabetes of adults (LADA). 
The development of T1D occurs over many years, usually initiated by genetic 
susceptibility or a viral attack. The appearance of β cell autoantibodies in the serum, 
along with progressive decline of β cell function and glucose tolerance in the prediabetic 
stage, eventually leads to the onset of overt diabetes. The most commonly used model 
for studying T1D is the non-obese diabetic (NOD) mouse model. Female NOD mice 
spontaneously develop immune infiltration (insulitis) of the islet at around 4 weeks and 
overt T1D by 12-13 weeks of age.  
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The mechanism underlying the development of T1D has been investigated for 
many decades now. Mutations in several genes, such as HLA-DQ/DR, IL-2RA, and 
CTLA-4 associate with increased susceptibility to T1D (178). A loss of both central and 
peripheral immune tolerance has also been postulated to contribute to the progression of 
T1D. During T cell development in the thymus, the transcription factor AIRE in medulla 
thymic epithelial cells is responsible for the transcription of a host of peripheral proteins, 
including insulin, that induce tolerance in naïve T cells to self antigens. Deletion of AIRE 
(179) or mutation of the INS promoter (180) can result in the onset of T1D, 
demonstrating a role for the loss of central tolerance in bringing about the onset of T1D. 
An imbalance between T effector cells (Teff) and T regulatory cells (Treg) or a reduction in 
Treg cells can also cause the inflammatory response mounted by the Teff cells to remain 
unchecked, and facilitate insulitis to continue. Furthermore, a reduction in the anti-
inflammatory cytokines such as IL-10 and TGF-β has also been suggested to contribute 
to an unabated immune response (reviewed in (178,181)).  
Several immunomodulatory drugs with well characterized responses in other 
autoimmune diseases have been attempted in clinical trials of new-onset T1D subjects. 
Whereas administration of some of these drugs (such as anti-CD3, anti-CD20, CTLA4-
Ig) have led to the preservation of β-cell function (as assessed by C-peptide secretion) 
for periods of months, subsequent declines in β-cell function paralleled those of placebo 
(182–185). In no case has true remission, as defined by insulin independence, been 
observed. These outcomes could be explained by the low replicative capacity of human 
β cells (186,187), coupled with the possibility that interventions were initiated too late in 
the disease—at a time in which molecular stress pathways in β cells were so 
aggressively activated that even a respite from autoimmunity could not prevent β-cell 
decline.  
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These considerations have sparked a new perspective in the field, in which 
greater emphasis has been placed on elucidating the molecular mechanisms within β 
cells that might initiate or perpetuate autoimmunity and eventual β cell demise. Eizirik et 
al showed that around 60% of known T1D candidate genes were expressed in human 
islets exposed to proinflammatory cytokines, demonstrating that the islet β cell plays an 
active role in the inflammatory process and perhaps, assists in its own demise (188). In 
addition, several studies have shown the presence of islet autoantibodies (189), β cell 
dysfunction (190,191) and metabolic alterations (192) years before diagnosis of T1D. 
Recent reports have shown that a host of alterations occurring in β cells could also 
contribute to the development of diabetes in the NOD mouse. Age dependent increase 
in expression of certain miRNA in prediabetic NOD mouse islets predispose the islet to 
death (193). Other reports have demonstrated the presence of increased ER stress in 
the new onset Type 1 diabetic β cell in humans (194)  and in the prediabetic NOD β cell 
(172,195). Tersey et al demonstrated that prediabetic mice showed dilated ER, an 
increase in UPR markers and reduced insulin secretion, possibly resulting in increased β 
cell death (196). Engin et al showed that pre-diabetic NOD mice treated with a chemical 
chaperone TUDCA decreases ER stress via ATF6 and therefore decreases β cell death 
(195). A recent study also showed evidence for autoantibodies against citrullinated 
GRP78 in prediabetic NOD mice, further strengthening the hypothesis that ER stress in 
the β cell enables its own death (197). ER stress is also associated with other 
autoimmune disorders such as colitis, rheumatoid arthritis and idiopathic inflammatory 
myopathies (198). Collectively, these findings suggest that, genetic susceptibilities of the 
β cell and/or early inflammation of the pancreas cause ER stress in the β cell, worsening 
of islet function and resulting in β cell death. Therefore, the β cell then assists in a 
vicious cycle that leads to its own death (Figure 5)  (198,199).   
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Therapies for T1D currently include administration of exogenous insulin, either in the 
form of injections or insulin pumps. In a DCCT (Diabetes Concentration and Control) 
trial, it was reported that patients with decreased insulin secretion were at a higher risk 
of developing diabetic retinopathy and nephropathy, indicating the importance of 
maintaining β cell function (200). Other therapeutic strategies such as islet 
transplantation and pancreatic transplantation could potentially increase endogenous C 
peptide levels, but these approaches have very low success rates. As T1D patients are 
known to have elevated β cell death rates (197), an ideal therapeutic approach for T1D 
would not only ameliorate the inflammatory milieu but also preserve β cell function.   
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Figure 5. The contribution of ER stress to type 1 diabetes. The prediabetic β cell is 
susceptible to cell death due to several factors. In response to cytokines, such as IL-1β, 
IFN-γ and TNF-α, the β cell expresses chemokines such as CCL2, CXCL1 and 
cytokines such as IL-6, potentially causing enhanced recruitment of immune cells and 
augmenting β cell death. The inflammatory milieu of the β cell and the presence of 
inherent genetic factors (such as decreased Pdx1 and Serca2b expression) contribute to 
the development of ER stress, resulting in the production of neo-antigens, cell death and 
an exacerbated immune response.  Furthermore, ER stress also activates the 
expression of NF-κB and TXNIP, which, in turn, increase cell death. Therefore, 
according to this model, the β cell actively assists in its own death.  
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Type 2 Diabetes: T2D is a metabolic disorder characterized by the presence of 
insulin resistance along with β cell dysfunction. T2D accounts for around 90% of 
diabetes cases, with around 300 million people projected to have T2D by 2025 (201). 
Risk factors such as genetic susceptibility, obesity and insufficient physical activity 
contribute to the development of T2D. Although insulin resistance was initially believed 
to be the principal cause of T2D, emerging evidence in the field suggests that β cell 
dysfunction acts as a key initiator in the onset of the disease. In the presence of chronic 
excess fuel, the β cell copes or compensates by enhancing insulin secretion or β cell 
mass. An inability of the β cell to sufficiently compensate can result in the onset of T2D. 
A loss in β cell function (202) accompanied by around 40-60% loss in β cell mass 
(203,204) has been shown to precede the development of disease. Furthermore, early 
loss of β cell function was observed in groups that were at risk to T2D, such as first 
degree relatives of T2D patients (205), Pima Indians (206) and women with gestational 
diabetes (207). Several genome wide association studies conducted on diabetic patients 
revealed more than 30 β cell loci associated with T2D (208–210), supporting the 
hypothesis that the islet β cell plays a crucial role in the progression of the disease.  
Glucolipotoxicity (chronic hyperglycemia and elevated free fatty acid levels in the 
body) can alter metabolic pathways in β cells, resulting in more malonyl Co-A and long-
chain acyl Co-A (LC-CoA) species, subsequently inciting lipogenesis and decreasing β 
cell function. Hyperglycemia results in a reduction in Insulin and β cell-specific 
transcription factors such as Pdx1 and MafA, further decreasing β cell function (reviewed 
in (44,211)). Excessive glucose metabolism results in increased reactive oxygen species 
production and oxidative stress, which can be toxic as the β cell has low levels of 
antioxidant enzymes (212–214). The resulting oxidative stress then decreases MafA 
expression and Pdx1 DNA binding ability (42), among a host of other effects, eventually 
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causing β cell dysfunction and cell death. Moreover, hyperglycemia and elevated free 
fatty acids increase the need for β cell insulin secretion, causing the endoplasmic 
reticulum (ER) to cope with the sudden insulin demand, potentially resulting in ER stress 
in T2D patients (215). Cytokines secreted by adipose tissue activates inflammatory 
pathways in the β cell (such as JNK and IKK), exacerbating oxidative stress and ER 
stress, which, if left unresolved, can result in further β cell death (reviewed in (133,165)). 
Essentially, the β cell in a type 2 and type 1 diabetic patient, is equivalent to a melting 
pot, wherein oxidative stress, inflammation, and ER stress pathways collide to instigate 
and aggravate β cell dysfunction and death. Medications for T2D include drugs that 
increase insulin sensitivity, such as thiazolidinediones, or enhance β cell function, such 
as increasing incretin levels by DPP-IV (dipeptidyl peptidase-IV) inhibitors and 
administration of sulfonylureas, which increase insulin secretion. However, long-term 
management of blood glucose levels can be difficult. After oral medications fail, insulin 
injections may become necessary for T2D patients.  
MODY: A form of diabetes referred to as maturity onset of diabetes (MODY) 
occurs in patients with mutations in certain genes expressed in β cells. The onset of 
MODY occurs around 25 years of age or younger. Patients suffering from MODY usually 
show impairments in glucose-induced insulin secretion and hyperglycemia without 
ketoacidosis. MODY2 is due to a mutation in the Glucokinase gene, whereas MODY1, 3, 
and 5 are due to mutations in the genes coding for transcription factors HNF4α, HNF1α 
and HNF1β. MODY4 and MODY6 are due to loss of function mutations in Pdx1 and 
NeuroD1. MODY reveals the importance of these transcription factors in β cell function 
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1.7 Hypothesis: 
β cell dysfunction and reduced survival are central to the development of 
diabetes. Research focusing on maintaining normal β cell function will provide useful 
insights for novel therapeutic strategies. In this respect, I have undertaken two series of 
experiments aimed at understanding transcriptional regulation in a normal β cell and 
translational stress response in type 1 diabetes. I hypothesize the following:  
 
1. Methylation of Pdx1 by Set7/9 enhances Pdx1 transcriptional 
activity and promotes β cell function. 
2. Pioglitazone treatment of prediabetic NOD mice improves β 
cell function, prevents β cell death and hence, reduces the 
autoimmune response.       
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CHAPTER 2: Materials and Methods 
 
Antibodies: Pdx1 antibody was obtained from Millipore (#07-696, 1:1000). Set7/9 
antibody was obtained from Cell Signaling (#2813, 1:1000). Monoclonal Flag M2 
antibody was obtained from Sigma-Aldrich (#F1804). Pdx1 K131-methyl antibody was 
generated in rabbits using the synthetic peptides C-Ahx-TKAHAW[K-Me1]GQWAG-
amide (Pdx1 K131me NT or Me-1) and Ac-AHAW[K-Me1]GQWAGGA-Ahx-KKC-amide 
(Pdx1 K131me CT or Me-2) by contract to 21st Century Biochemicals. Pdx1 K131-methyl 
antibody was used at a dilution of 1:5000. Gapdh antibody was obtained from Ambion 
(#AM4300, 1:4000).  Other antibodies used are as follows: Bip (Cell Signaling, #3183, 
1:1000 dilution), ATF4 (Santa Cruz, #sc-200, 1:500 dilution), Actin (MP Biomedicals, 
#691001, 1:1000 dilution), GAPDH (Ambion, #AM4300, 1:4000 dilution), Pdx1 (Millipore, 
#07-696, 1:1000 dilution), and TXNIP (Santa Cruz, #sc33099, 1:500 dilution).  
Fluorophore-labeled secondary antibodies IRDye 700 and IRDye 800 were obtained 
from Licor Biosciences.  
Vectors:  Plasmids were generated using standard recombinant techniques. PCR-
generated constructs were verified by automated sequencing. Recombinant protein was 
expressed using the Escherichia coli expression vectors pET21d, that contained a T7 
promoter driving the expression of full length Syrian hamster Pdx1 and truncated 
mutants Pdx1 homeodomain, Pdx1 homeodomain and C terminal (216). Wildtype 
human Pdx1 was PCR amplified from the origene cDNA (NM_000209) and then ligated 
into Nde1 and BamH1 sites in the pET15b vector, which contains an in frame C term 
6XHis tag. Recombinant human Pdx1 point mutants were also expressed using the 
pET15b expression vector. The N terminus Pdx1 protein (1-137 aa) was PCR amplified 
41 
 
from the pET15b vector containing human Pdx1 insert, using primers that incorporated a 
Nde1 and Sal1 restriction site and stop codon in the forward and reverse primer 
respectively. The amplified product was cloned into a pCR2.1-TOPO vector (Invitrogen, 
K4550-01) and then cleaved and ligated into the Nde1/Xho1 sites in pET15b backbone 
vector. Primers used to clone the N terminus of human Pdx1 were: 5’- 
CATATGAACGGCGAGGAGCAGTA -3’ and 5’-
CTCGAGTTATTAGCCGCCTGCCCACTGGCCTT -3’.  Point mutants were generated 
using the Quick Change® site directed mutagenesis kit (Agilent). The following primers 
were used to make the respective point mutants:  K123R: 5’-
CAGCTGCCTTTCCCATGGATGAGGTCGACCAAAGCTCAC-3' and 5'-
GTGAGCTTTGGTCGACCTCATCCATGGGAAAGGCAGCTG-3'. K126R: 5'-
TCCCATGGATGAAGTCTACCAGAGCTCACGCGT-3' and 5'-
ACGCGTGAGCTCTGGTAGACTTCATCCATGGGA-3'.  K131R: 5'-
CCAAAGCTCACGCGTGGAGAGGCCAGTGG-3' and 5'-
CCACTGGCCTCTCCACGCGTGAGCTTTGG-3'.  CMV promoter-driven vectors 
(pBAT12) were used to express wildtype and mutant Pdx1 in HEK293 and NIH3T3 cells. 
The CMV promoter –driven point mutants were made using the same primers, as 
mentioned above. However, to make the K123R mutant in the pBAT12 HA vector, the 
following primers were used: 5’-
TCAGCTCCCTTTCCCATGGATGAGATCCACCAAAGCTCA-3’ and 5’- 
TGAGCTTTGGTGGATCTCATCCATGGGAAAGGGAGCTGA-3’. The CMV promoter-
driven vector used to drive Setd7 was described previously (108). The reporter plasmids 
5FF and Gal4-UAS is as previously described (85).  
Animal Models: All animal studies were reviewed and approved by the Indiana 
University Institutional Animal Care and Use Committee. Setd7Loxp/+ mice, in which Cre 
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recombinase recognition sequences (Loxp) flank exon 2, were generated by subcontract 
to Ingenious Targeting Labs. The neomycin selection cassette was removed by crossing 
Setd7Loxp/+ mice to the FLPR strain. Mice were backcrossed onto the C57BL/6 
background for 10 generations. MIP1-CreERT mice on the C57BL/6 background were 
kindly provided by Dr. L. Philipson (217). For induction of Cre-mediated recombination, 
mice were orally gavaged with tamoxifen dissolved in peanut oil (mixed for 1 hour at 
550C) at a dose of 5 mg/day/mouse. Pdx14.7-Cre mice were kindly provided by Dr. G. Gu 
(Vanderbilt University), which were crossed onto the Setd7Loxp/+ mice on a mixed 
background to generate pancreas specific Set7/9 knockout mice (Set7/9Δpanc). The 
expression of Set7/9-FLAG transgene in the pancreas was driven by a 4.7 Kb Pdx1 
promoter (218). Two germ line transmissible founders, pSet7/9Tg J and K, having high 
and low flag expression were phenotyped. Both founder lines were present on a mixed 
background. pSet7/9Tg J was chosen for further studies. Five week-old female NOD 
mice were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were allowed to 
acclimate for 1 week prior to experimentation. Mice were fed with either a standard chow 
diet or a standard chow diet containing 0.01 wt% pioglitazone (Harlan-Teklad Global, 
Indianapolis, IN). This concentration of pioglitazone was designed to deliver 
approximately 20 mg/kg body weight pioglitazone (based on average daily food intake). 
Mouse islets were isolated from pancreas (219) and then handpicked and cultured in 
RPMI medium (11mM glucose) for around 1 hour or overnight for RNA/protein analysis 
and GSIS assays respectively. 
Cell culture: The mouse fibroblast cell line NIH3T3 was maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% Newborn Calf serum, 1%Sodium 
pyruvate, 100ug/ml Penicillin and 100ug/mil Streptomycin. The human embryonic kidney 
cell line, HEK293, and the rat insulinoma cell line INS-1 832/13 were maintained in 
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RPMI-1640 medium (11mM glucose), supplemented with 10% fetal bovine serum, 2mM 
L-glutamine, 1mM sodium pyruvate, 50uM β-mercaptoethanol (Ins-1 mix), 10mM 
HEPES, 100ug/ml Penicillin and 100ug/ml Streptomycin. All cell lines were cultured at 
370C in humidified chambers with 5% CO2.  
Reagents: Recombinant Set7/9 protein (#ENZ-314) was purchased from Prospec. The 
inhibitor BP-107-7 (Figure. 10D) was synthesized by employing a similar procedure as 
described previously (220,221).   Overall % yield = 38%. 1H NMR (CD3OD): δ 7.45-7.27 
(m, 20H), 6.67 (s, 2H), 3.78 (t, 4H, J = 5.76 Hz), 3.00-2.94 (m, 8H), 1.72-1.69 (m, 4H), 
1.55 (b, 4H), 1.48 - 1.46 (m, 2H). 13C NMR (CD3OD): δ 141.72, 132.48, 129.62, 128.23, 
127.27, 127.07, 61.38, 47.04, 44.50, 40.12, 26.43, 25.83, 25.22, 23.10. HRMS 
calculated 666.35, found 667.2 ([M+1]+). Melting point is 178-181°C. UPLC retention 
time is 2.65 min using a Waters® UPLC instrument fitted with an Acquity UPLC BEH 
C18, 1.7µm column (2.1 X 50 mm), 5-10% acetonitrile in water (0.1% TFA) during a 5 
mins run.  
Protein Purification: 6X-His tagged Pdx1 wildtype and mutant proteins were 
overexpressed in BL21DE3/pLysS using the pET expression system (Novagen). 
Cultures were grown up to log phase at 370C, with an OD600= 0.6-1.0 in 1l of Luria 
Bertani Culture. Over expression of recombinant proteins were induced by the addition 
of 1mM IPTG. Thereafter, cultures were grown overnight at 300C and pelleted by 
centrifugation at 4000 rpm for 15min. Pellets were resuspended in 25 ml Lysis buffer 
(50mM NaH2PO4, pH 8.0, 300mM NaCl, 5mM imdiazole, 10mM DTT, 5% glycerol, 40U 
of lysozyme/ml of culture (novagen) and 25U per 1ml of original culture, novagen) and 
incubated in ice for 1 hour. The lysates were sonicated at a setting of 10, for 10s bursts, 
15 times and then centrifuged at max speed for 10 min at 40C. The resulting supernatant 
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was incubated with 5ml of Ni-NTA resin (Qiagen) for 1 hour at 40C, following which it 
was transferred into a 25ml column (BioRad) and allowed to flow at a gravity rate, and 
the eluate was collected in 1.5 ml eppendorf tubes. The protein was eluted with an 
increasing imidzaole gradient (10mM-250mM) of lysis buffer (10ml). Fractions were 
collected and protein concentrations were determined using Lowry’s assay (BioRad). 
The fractions were resolved on a 12% SDS-PAGE and then stained by coomassie blue  
Methylation Assay: Purified Pdx1 protein (150 nM – 1.2 μM) and Set7/9 protein (200 
nM) were incubated at 30°C for 3 hours in a reaction buffer containing 50mM Tris (pH 
8.5), 4mM DTT, 5mM MgCl2 , 0.05mg/ml BSA, 1 μM 3H-AdoMet or 50 μM AdoMet in 
20μl volume. The reaction was stopped by the addition of 6X SDS gel loading buffer. 
The samples were then resolved by 10% SDS-PAGE gel, followed by coomassie stain to 
verify loading. The gel was further incubated with En3hance solution (Perkin Elmer), 
washed three times with water (10 minutes) and dried under vacuum at 700C for 1 hour.  
The gel was exposed to Kodak XAR film for 24-48 hours at -800C. Quantification was 
done using the ImageJ software. 
Immunoblot Assay: Lysis Buffer used contains 0.05% Sodium deoxycholate, 10%NP-
40, 0.1% SDS, 0.2% Sarcosyl, 10% Glycerol, 1mM DTT, 1mM EDTA, 10mM Sodium 
Fluoride, 50mM Tris-HCl (pH 8.0) brought up to 500ml with 1X PBS (Phosphate buffered 
Saline, pH 7.2). Prior to use, 20ul of 1M MgCl2, 5ul Benzonase, 1 table of min-EDTA 
inhibitor and protease inhibitor (Roche) were added to 10 ml lysis buffer and mixed. For 
lysis of isolated islets, the SDS concentration was increased to 2% SDS. Samples were 
resolved on 10% polyacrylamide gels and were then transferred onto a PVDF 
membrane (Immobilon-FL, Millipore). Membranes were blocked with Odyssey blocking 
buffer (Li-Cor Biosciences) for 1 hour at room temperature and exposed to primary 
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antibody, overnight at 40C. The following day, the membrane was washed three times 
with 0.05% PBS-Tween 20 and exposed to Li-Cor fluor tagged secondary antibody 
(1:10,000) for 1 hour, following which, the membrane was washed three times with 
0.05% PBS-Tween 20 again and visualized and quantified using the Li-Cor Odyssey 
system. Dot Blot was performed on a PVDF membrane (Millipore), using the Bio-Dot 
Apparatus (#170-6545) using the Pdx1 methyl antibody and the unmodified Pdx1 
peptide, the Pdx1 K131me NT and Pdx1 K131me CT peptide (described under 
antibodies). 
Nuclear Extraction: 10cm plates of cultured cells were washed twice with 1X PBS 
followed by a 10 min incubation with hypotonic buffer (10mM Hepes, pH 7.9, 10mM KCl, 
0.1mM EDTA, protease and phosphotase inhibitors). 25ul of 10% IGEPAL was added to 
each plate, for 2 min, to disrupt the plasma membrane. The cells were scrapped and 
centrifuged at 6000rpm for 3 minutes. The supernatant which is the cytoplasm is 
transferred to another tube. Around 100ul of lysis buffer (described above) was added to 
the nuclear pellet, followed by incubation at the 40C for 2 hours or sonication, followed by 
centrifugation at maximum speed for 10 minutes. After protein determination, the nuclear 
lysates is stored at -800C or used for further analysis. 
Co-immunoprecipitation Assays: For detection of methylation, 10 cm plates cultured 
with HEK293 cells transfected with 5ug Pdx1 or 5ug Set7/9 expression plasmids or INS-
1 832/13 cells treated overnight with BP-107-7 was used. Around 48 hours later, cells 
were washed twice with ice cold PBS and whole cell extracts were determined for 
protein. The lysis buffer used was the same as that described for immunoblot, but 
prepared without DTT and SDS. 1mg of HEK293 whole cell lysates or 500ug of INS-1 
832/13 nuclear extract was incubated along with beads and antibody overnight. Prior to 
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overnight incubation, 20ul of the reaction is collected as input. The beads were 
subsequently washed three times with lysis buffer and the eluted protein was obtained 
with boiling SDS sample buffer. The sample was then analyzed by immunoblot analysis. 
Immunoprecipitation reactions for HA-tagged Pdx1 from HEK293 whole cell lysates was 
performed using the Pierce HA-tag IP kit (26180) according to manufacturer’s 
instructions. Immunoprecipitation assays for methylated Pdx1 were conducted using 
20ul Protein A Dynabeads (Novex, Life technologies), incubated with 4ug anti methyl-
lysine antibody (Cayman chemicals, #13727). Co-immunoprecipitation assays from 
NIH3T3 cells transfected with Pdx1 and Set7/9 were performed using Invitrogen Protein 
G dynabeads incubated with Flag antibody (Sigma). Nuclear extracts were sonicated to 
shear DNA and then subjected to co-immunoprecipitation assay. For protein elution from 
dynabeads, the samples were incubated for ten minutes with 20ul SDS sample buffer at 
700C. 2% input, along with the eluted protein is analyzed using a 12% SDS-PAGE gel 
and subjected to immunoblot analysis.  
Quantitative Real-Time Reverse Transcriptase RT-PCR: Approximately 106 β cells or 
75-100 islets were lysed in 350ul of RLT buffer (Qiagen) containing 1% β-
mercaptoethanol. Samples were sheared through a 27- guage needle. The Qiagen 
RNeasy Plus micro kit (#74034) and RNeasy Plus mini kit (#74134) were used for RNA 
isolation from islet and cell line samples respectively. 5ug of total RNA was reverse 
transcribed to cDNA at 370C for 1 hour using 5ug random hexamers, 0.5mM dNTP, 5X 
first strand buffer, 0.01mM DTT and 200 units of MMLV reverse transcriptase 
(Invitrogen) in a final reaction volume of 20ul. The resulting cDNA was diluted with 
RNase free water in 1:100 ratio. The real-time PCR reaction was performed using Sybr 
Green, 2.5mM MgCl2, 1X PCR buffer (10Mm Trish HCl, pH 8.3, 50mM KCl), primer mix 
(0.2uM of each primer) and Taq polymerase (Sigma). The threshold cycle (CT) 
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methodology was used to calculate relative quantities of mRNA products from each 
sample, and all samples were corrected for total RNA by normalizing CT values to the CT 
value of Actb message. All data represent the average of triplicate determinations from 
at least three independent experiments. Primers used for Pdx1 (QT00102235), Slc2a2 
(QT00103537), Gck (QT00140007), MafA (QT00298718) were obtained from Qiagen 
Quantitect Sybr Green kit. Primers used for Ins1/2, Insulin pre-mRNA and Actb are as 
described previously (72). Other primers described previously include Xbp1s, Atf4 (196), 
Gpx1 and Sod1 (222). Primer for mouse Txnip was 5’- 
GTGCAGAAGATCAGACCATCC-3’ and 5’- AGCCAGGGACACTGACGTA-3’. For rat 
Txnip, the following primers were designed and verified to amplify the expected 
sequence with appropriate linearity:  5’-TCCATCCACGCTGACTTTGAG -3’, and 5’-
CCCTGAGATAATGTGATTGCCTCTG-3’.  Measurement of methylated and 
unmethylated preproinsulin DNA in the serum by multiplex PCR was performed as we 
recently detailed (223).   
Luciferase Assay: 5x105 NIH3T3 cells were transfected with 1µg of reporter plasmid 
(5FF or Gal4-UAS reporter plasmid), 0.1µg of pbat12 or wildtype or mutant Pdx1 
transgene and 0.5µg of Set7/9 expression plasmid. Transfections were performed using 
6ul of metafectene pro (Biontex) per well.  After 48 hours, whole cell extracts were used 
to assess luciferase activity using a commercially available luciferase assay kit 
(Promega), as per kit instructions. Whole cell lysates were determined for protein 
concentration and lysates were analyzed for Pdx1 and Set7/9 levels using immunoblot 
assay.  
Labeling of EMSA probes: Insulin minienhancer probes, containing the E2/A3/A4 
element, were used for to determine Pdx1 binding affinity. The top and bottom strand 
sequences were the following:  
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GATCCTTCATCAGGCCATCTGGCCCCTTGTTAATAATCTAATTACCCTAGGTCTAA, 
GATCTTAGACCTAGGGTAATTAGATTATTAACAAGGGGCCAGATGGCCTGATGAAG 
The top strand was 5’- end labeled with γ-32P ATP using T4- poly nucleotide kinase in 
STE buffer (10mM Tris pH 7.5, 1mM EDTA, 100mM NaCl) and annealed with unlabelled 
bottom strand at room temperature. Approximately 20000 counts of probe was used for 
each reaction in the EMSA assay.    
Electrophoretic Mobility Shift Assay (EMSA): NIH3T3 cells were transfected with 
wildtype or mutant Pdx1, with or without Set7/9. Nuclear extracts were sonicated to 
shear DNA, measured for protein and then quickly frozen in liquid nitrogen and stored at 
-800C or used for the EMSA assay. 1ug of nuclear extract was used to perform the 
EMSA reaction. The EMSA reaction consisted of labeled probe, nuclear extract, 1ug 
poly-dI/dC, 1ug BSA and binding buffer (50mM Hepes, pH 7.9, 375mM KCl, 12.5mM 
MgCl2, 0.5mM EDTA, 5mM DTT, 15% Ficoll), with or without increasing concentrations 
of cold probe. The reaction was incubated at room temperature for 15 minutes and was 
then resolved on a 5% polyacrylamide gel at 150V and then subsequently dried in a gel 
drier for 2 h, at 700C. The gel was exposed to a phosphoimager screen (Molecular 
Dynamics) overnight and imaged the next day. Competition EMSAs were modeled on 
the basis of single-phase exponential dissociation using the non-linear least squares fit 
algorithm in Prism 5.0 software (GraphPad), and apparent dissociation constants were 
determined as described previously (216) 
Mass spectrometry analysis: Samples (proteins from in vitro experiments and from 
MIN6 cells) were first denatured with 8M urea, then reduced with 10 mM DTT in 10 mM 
ammonium bicarbonate and alkylated with 55 mM iodoacetamide (prepared in 10 mM 
ammonium bicarbonate), and then digested with trypsin, incubated overnight at 37°C. 
The samples in vitro were analyzed using Thermo-Fisher Scientific LTQ Orbitrap Velos 
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Pro and Surveyor HPLC. Tryptic peptides were injected onto the C18 column. Peptides 
were eluted with a linear gradient from 3 to 40% acetonitrile (in water with 0.1% FA) 
developed over 90 minutes at room temperature, at a flow rate of 60ul/min, and effluent 
was electro-sprayed into the LTQ mass spectrometer. Blanks were run prior to the 
sample run to make sure there was no significant signal from solvents or the column. 
The TSK gel columns (ODS-100 V, 3 μm, 1.0 mm × 50 mm) were used for the Surveyor 
HPLC system. The trypsin digested Pdx1 immunoprecipitants from MIN6 cells were 
pressure loaded onto a 12 cm multidimensional protein identification technology 
(MudPIT) column as previously described (224). Peptides were analyzed by MS/MS on 
an LTQ XL mass spectrometer following elution during a 10- step MudPIT run. Protein 
database searches were performed using SequestR algorithms within Proteome 
Discoverer (Thermo) against appropriate FASTA sequence databases obtained from 
UniProt. Database searches included dynamic modification analysis for mono-, di-, and 
trimethylated Lys residues, and Met residue oxidation.  
Tissue Fixation: Pancreata was harvested immediately after the animal was sacrificed. 
The pancreas was then placed in 4% paraformaldehyde for 2 hours at 40C, followed by 
two 1X PBS washes (15 minutes each) at room temperature. The pancreata are then 
washed in 25%, 50% and 70% ethanol for 15 minutes each at room temperature, 
followed by paraffin embedding. The pancreata from the NOD mice were heart perfused 
with PBS and 4% PFA, followed by transfer of the pancreata to 4% paraformaldehyde 
overnight at room temperature. The pancreata were further fixed for 1 hour with 4% 
paraformaldehyde, followed by two 1 hour washes with PBS, a one hour wash each with 
50% and 70% ethanol and paraffin embedding. The pancreata were then sectioned into 
5 μm sections, with every alternate section being collected for analysis. 
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Immunhistochemistry: Paraffin was removed from tissue sections by submersion in 
xylene, 100%, 95%, 70% ethanol and H2O for 5 minutes each. For staining with HRP 
secondary antibodies, the endogenous peroxidase activity was quenched by submersion 
of slides in a mixture of methanol and H2O2 for 30 minutes. The antigens were 
unmasked by heating the slides immersed in unmasking solution (Vector Labs) at 950C 
for 20 minutes. The slides were cooled to room temperature and blocked with 2.5% Goat 
serum for 30 minutes. After blocking, the slides were incubated with primary antibody 
overnight at 40C. The sections were washed with PBS three times and exposed to Alexa 
fluor anti-mouse, anti-rabbit, anti-guinea pig (568 and 488) secondary antibodies for 1 
hour at room temperature and DAPI (Invitrogen) for 3 minutes. In the case of staining 
with HRP-conjugated secondary antibody (Vector Labs), the sections were then exposed 
to either Vector NovaRed or Vector DAB substrate, followed by hemotoxylin staining. 
The slides were visualized using an LSM 700 confocal microscope (Zeiss, Thornwood, 
NY).  
Insulitis Scoring and β cell area: Pancreatic sections were immunostained for insulin 
and counterstained with hematoxylin. For insulitis scoring, 3 pancreas sections at least 
75 μm apart from 5 animals per group were scored using the following grading scheme 
(33): grade 1 – no islet-associated mononuclear cell infiltrates; grade 2 – peri-insulitis 
affecting less than 50% of the circumference of the islet without evidence of islet 
invasion; grade 3 – peri-insulitis affecting greater than 50% of the circumference of the 
islet with evidence of islet invasion; grade 4 – islet invasion. The sections were 
visualized using a Zeiss Axioskop 40 microscope. Three pancreatic sections, 75 μm 
apart, were stained for insulin using the Vector Labs kit (described above), and 
evaluated for insulin+ cells. Images were taken with the Axio-observer Z1 microscope 
(Zeiss) equipped with a Orca ER CCD camera (Hamamatsu).                          
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Glucose tolerance test: Glucose tolerance tests (GTTs) were performed on mice 
starved overnight. After 2 g/kg glucose was injected intraperitoneally, blood glucose 
concentration was monitored at 0, 10, 20, 30, 60, 90 and 120 minutes, using an 
AlphaTrak glucometer (Abbott, Abbott Park, IL). The values are plotted on a graph and 
Area under the Curve is calculated using Prism 5 Software. To determine insulin 
secreted in vivo, in response to intraperitoneal glucose injection (2g/kg), blood was 
collected from the tail at 0, 2 and 10 minutes and serum was obtained by spinning the 
tubes at 5000rpm for 20 minutes, at 40C. Serum insulin was measured using an Ultra 
Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL). Serum proinsulin 
was measured using a Proinsulin Rat/Mouse ELISA kit (Mercodia, Winston Salem, NC). 
Insulin Tolerance test (ITT): Random-fed (or free-fed) mice were injected with 1.5U/kg 
insulin (Humulin R, Eli Lilly) and blood glucose was measured at 0, 10, 20, 30, 40, 50 
and 60 minutes. The blood glucose at each time point was calculated as % of basal 
blood glucose and plotted against time. Area under the curve was calculated taking % of 
basal blood glucose at 0 minutes as the baseline. Calculations were performed using 
Prism 5 software. 
Glucose stimulated insulin secretion (GSIS): Islets were harvested and allowed to 
recover overnight in RPMI medium containing 11mM glucose. The next day, islets were 
transferred to KRB buffer (115mM NaCl, 5.9mM KCl, 1.2mM MgCl2, 1.2mM NaH2PO4, 
1.2mM Na2SO4, 2.5mM CaCl2, 25mM NaHCO3, 0.05% BSA) and first incubated in 2.5 
mM D-glucose for 1 hour, followed by 25 mM glucose for 1 hour. Insulin levels in the 
supernatant and the total cell lysate were measured using a Mouse Insulin ELISA kit 
(ALPCO, Salem, NH).  
DEXA Scanning: Lean body mass and fat mass was determined by dual-energy x-ray 
absorptiometry (DEXA) using a Lunar PIXImus2 Densitometer (GE Medical Systems). 
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Flow cytometric Analysis of T cells: Spleen and pancreatic lymph node samples were 
pulverized and passed through a cell strainer (BD Falcon 352350), followed by treatment 
with red blood cell lysis buffer (155mM NH4Cl, 12mM NaHCO3, 0.1mM EDTA) for 3 min 
and two washes with 1X PBS. For Treg cell analyses, equal volumes of the single cell 
suspensions (at least 105 cells) were stained using anti-CD4-fluorescein isothiocyanate 
(clone RM4-5, eBioscience, San Diego, CA) and anti-CD25-APC (PC61.5, eBioscience) 
antibodies and fixed overnight before being permeabilized and stained with anti-Foxp3-
phycoerythrin (FJK-16s, eBioscience) antibody.  For the Th1 and Th17 cell analyses, 
equal volumes of the single cell suspensions were first incubated with Cell Stimulation 
Cocktail (eBioscience) for 4 hours prior to staining with anti-CD4 antibody; cells were 
fixed overnight then permeabilized and stained for IL-17A (eBio17B7) and IFNγ 
(XMG1.2) according to manufacturer’s instructions (eBioscience). Cells were analyzed 
using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and FlowJo 
software (TreeStar, Ashland, OR). 
To assess cell proliferation, single cell suspensions of cells were incubated in 5 μm 
membrane dye carboxyfluorescein diacetate succinimidyl ester (CFSE) for 10 min at 37 
°C, diluted with 5 volumes of ice-cold media, and incubated for 5 min on ice. Samples 
were then washed with PBS three times and subjected to stimulation in vitro. For flow 
cytometric analyses following stimulation in vitro, single cell suspensions were made 
from spleens harvested from mice as described above. 106 cells were cultured in the 
presence of 75 units/ml recombinant human IL-2 (ProSpec), DMSO or 1 or 10uM 
pioglitazone and activated with anti-CD3/anti-CD28 antibody-coated beads (Invitrogen) 
at a concentration of one bead/cell for 4 days. Cells were then harvested, nonspecific 
Fc-mediated interactions were blocked with anti-CD16/32 (clone 93), and cells were 
stained as described above for the examination of Treg, Th1, and Th17 cell populations. 
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The LIVE/DEAD® Fixable Violet Dead Cell Stain kit (Invitrogen) allowed for the 
exclusion of dead cells. Cells were analyzed using a BD LSRII flow cytometer (BD 
Biosciences) and FlowJo software. 
Unmethylation Index: DNA was extracted from 20ul of serum from control and 
pioglitazone treated NOD mice using the ZR Serum DNA kit (D3013, Zymo Research 
Corp, Orange, California). All DNA samples underwent bisulfite treatment using the EZ 
DNA Methylation kit (D5001, Zymo Research). The PCR assay used was a dual 
fluorescent probe-based multiplex assay (AHMSN8K; Life Technologies, Gaithersburg, 
Maryland). For amplification of the mouse 2 PPI promoter, the following primers were 
used: 5′-AATTGGTTTATTAGGTTATTAGGGTTTTTTGTTAAGATTTTA-3′ (forward); 5′-
ACTAAAACTACAATTTCCAAACACTTCCCTAA-3′ (reverse). For detection, the 
following probes were used: 5′-CTCATTAAACGTCAACACC-3′ (VIC); 5′-
CTCATTAAACATCAACACC-3′ (FAM). The PCR reaction also contained TaqMan 
Universal PCR Master Mix, No AmpErase UNG (Life Technologies) and the reactions 
were cycled 60 times using the following conditions: 92°C for 15 seconds followed by 
60°C for 90 seconds. The formula 2^ (Vic CT- Fam CT) was used to calculate the 
unmethylation index.  
Statistics: All data are presented as the mean +/- SEM. One-way ANOVA (with 
Dunnett’s post-test) was used for comparisons involving more than two conditions, and a 
two-tailed Student’s t test was used for comparisons involving two conditions. Prism 
software version 5.0 (GraphPad Software, San Diego, CA) was used for all statistical 
analyses. Statistical significance was assumed at P < 0.05. 
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CHAPTER 3: Transcriptional Activity of the Islet β Cell Factor Pdx1 is Augmented 
by Lysine Methylation Catalyzed by the Methyltransferase Set7/9 
 
In this chapter, I explore the impact of the interaction between β cell transcription factor 
Pdx1 and its cofactor Set7/9 on transcription of Pdx1 target genes and β cell function.  In 
particular, I test the effect of Set7/9 mediated methylation of Pdx1 transcription and 
investigate the possibility of methylation as another regulatory level of Pdx1 function. 
 
3.1 Introduction 
Deficiency of insulin secretion underlies the transition from normoglycemia to 
hyperglycemia in both type 1 and type 2 diabetes (225,226). Circulating insulin arises 
almost exclusively from islet β cells in the pancreas, but our understanding of the 
molecular mechanisms governing β cell function in health and disease remains 
incomplete. A key protein that is essential for β cell function is the homeobox 
transcription factor Pdx1. During mammalian development, Pdx1 is essential for 
pancreas organogenesis  (227–229). In the adult pancreas, Pdx1 is restricted primarily 
to β cells and is responsible for the regulation of genes that are essential to β cell 
function, proliferation, and survival (230,231). In this context, elucidating the molecular 
mechanisms of Pdx1 action will be crucial in future attempts to restore β cell function in 
the setting of diabetes. 
The interaction of Pdx1 with other transcription factors and cofactors appears to 
be important in modulating Pdx1 activity (positively or negatively) at a given target gene. 
For example, the formation of a transcriptional complex between Pdx1 and the basic 
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helix-loop-helix factor NeuroD1 in β cells results in the formation of a complex with the 
gene encoding preproinsulin (Ins1/2) that permits synergistic activation of transcription 
(232,233). By contrast, interaction of Pdx1 with PCIF1 results in degradation of Pdx1 
protein by the proteasome and consequent reduction in Pdx1 activity (234). Interactions 
such as these suggest a model whereby various aspects of Pdx1 activity, including DNA 
binding affinity, protein stability, and recruitment of basal transcriptional machinery are 
modulated to achieve homeostatic function of the β cell. 
Our laboratory has previously reported that the lysine methyltransferase Set7/9 
interacts with Pdx1 to promote transactivation of an Ins1/2 mini-enhancer (235) that 
contains the classical Pdx1 binding sequence (5’-TAAT-3’) present in elements A3 and 
A4. Augmentation of transcriptional activity was correlated with an increase in Lys4 
methylation of histone 3 (H3) and the conversion of the initiating isoform of RNA 
polymerase II to its elongating isoform. In recent years, several reports suggested that 
the methyltransferase activity of Set7/9 is not restricted only to Lys residues on histones, 
but includes Lys residues of other proteins, such as p53, p65, and estrogen receptor-α, 
among others (236–239). These varied methylation events were shown to alter the 
activity or half-life of these proteins, emphasizing that Lys methylation (similar to Ser/Thr 
phosphorylation or Lys acetylation) modulates transcription factor function (240,241).   
In light of these new perspectives on Lys methylation and Set7/9 action, we 
asked if the interactions between Set7/9 and Pdx1 might affect Pdx1 activity 
independently of effects on histones. In this study, our findings reveal a heretofore 
unappreciated role for Lys-specific methylation of Pdx1 by Set7/9 in the maintenance of 
normal β cell function.   
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3.2 Results 
A. Pdx1 is methylated by Set7/9 in vitro at positions K123 and K131 
Recent evidence suggesting that Set7/9 methylates non-histone proteins led us 
to investigate first if the interaction between Set7/9 and Pdx1 leads to Lys methylation of 
Pdx1. We performed methylation reactions in vitro using purified Pdx1 and Set7/9 
proteins and 3H-S-adenosyl methionine (3H-AdoMet). Incorporation of 3H-methyl group 
into Pdx1 in this reaction is evidence of protein methylation (235). As shown in Fig. 6A, 
3H-methyl was incorporated into Pdx1 in a concentration-dependent manner, and only in 
the presence of Set7/9. By contrast, no methylation of bovine serum albumin is observed 
in the same reaction, suggesting that the methylation is specific for Pdx1 (Fig. 6A).   
Prior studies suggest that Lys residues in a broad range of sequence contexts 
can serve as substrates for Set7/9 (242). Within Pdx1, Lys residues occur in both the N-
terminal transactivation domain (residues K15, K123, K126, K131) and the DNA binding 
homeodomain (residues K147, K163, K191, K200, K202, K203, K207, K208). To narrow 
the possible Lys residues that may be methylated by Set7/9, we next performed 
methylation assays using different truncated mutants of Pdx1, as shown in Fig. 6B. 
Surprisingly, none of the truncated mutants were methylated by Set7/9 in vitro; 
suggesting that methylation of Pdx1 required the structural context of the full-length 
protein.   
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Figure 6. Pdx1 methylation by Set7/9 in vitro. (A) Methylation assay in vitro using 
recombinant Set7/9, 3H-AdoMet, and increasing concentrations of Pdx1 protein was 
performed, then reactions were subjected to polyacrylamide gel electrophoresis. Upper 
panels show fluorography for 3H and lower panels show corresponding Coomassie 
staining of the same gel; (B) Methylation assay in vitro using recombinant Set7/9, 3H-
AdoMet, and full-length or truncated Pdx1 proteins was performed, followed by 
polyacrylamide gel electrophoresis. Schematic representation of truncated mutants of 
Pdx1 is shown in the right, and corresponding 3H fluorography and Coomassie stains are 
shown on the left; (C) Methylation assays in vitro using wild-type (WT) and mutated 
Pdx1 proteins was performed, with corresponding quantitation of methylated Pdx1 
protein intensities (normalized to total Pdx1 protein by Coomassie staining). All images 
shown are representative of at least N=3 experiments. *p<0.05 compared to wild-type 
Pdx1. 
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Figure 7. MS/MS spectra of Pdx1 in vitro and in MIN6 cells. (A) Tandem mass 
spectrum of the peptide GQLPFPWMK showing modification of K123 with mono-
methylation (+14 dalton) following treatment with recombinant Set7/9 in vitro. The 
SEQUEST XCorr for this +2 peptide is 1.83 with a ppm of -1.65; (B) Tandem mass 
spectrum of the +3 peptide AHAWKGQWAGGAYAAEPEENKR showing mono-
methylation (+14 dalton) of K131 in Pdx1 following treatment with recombinant Set7/9 in 
vitro. The SEQUEST XCorr for this peptide is 6.19 with a ppm of 0.34; (C) 
Representative MS/MS spectrum from an LTQ ion trap for the +2 peptide 
AHAWKGQWAGGAYAAEPEENKR showing tri-methylation at K131 in Pdx1 in 
transduced MIN6 β cells. The SEQUEST XCorr for this peptide is 2.24 with a ppm of 
19.25.  
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To identify the methylated Lys residue(s) in the full-length protein, we next 
performed mass spectrometry of methylated full-length Pdx1. Broad coverage of the 
peptides confirmed the mono-methylation of Pdx1 at two Lys residues in the N terminal 
region of the protein residues K123 and K131 (Fig. 7A and B).  Data from the mass  
spectrometric analysis was verified using mutated Pdx1 proteins, in which residues 
K123, K126, and K131 in the N-terminal domain were mutated to Arg (K123R, K126R, 
and K131R). As shown in Fig. 6C, reductions in methylation of Pdx1 clearly occurred in 
K123R mutant, but no statistically significant reduction was seen in the K131R mutant.  
Little residual methylation was observed in the K123R+K131R double mutant. Together, 
these data suggest that residue K123 appears to be the kinetically preferred site for 
methylation by Set7/9 in vitro, with evidence of lesser methylation occurring at K131.  
B. K131 of Pdx1 is required for transcriptional augmentation by Set7/9 
In prior studies, we showed that Set7/9 augments the transcriptional activity of 
Pdx1 in the context of a Pdx1 reporter (containing 5 tandem Pdx1 binding sites); this 
result was previously ascribed to Set7/9-mediated methylation of H3 (residue K4) at this 
reporter (235). Based on our results in Fig. 6, we considered the possibility that this 
transcriptional augmentation by Set7/9 might instead be a result of Pdx1 Lys 
methylation. To test this possibility, we performed reporter gene activity assays using 
wild-type and mutated Pdx1 in the mouse-derived cell line NIH3T3, which is devoid of 
endogenous Pdx1. As shown in Fig. 8A, when a cDNA encoding wild-type Pdx1 is co-
transfected into NIH3T3 cells with a Pdx1 reporter plasmid containing tandem copies of 
a Pdx1 binding sequence (derived from the rat Ins1 E2/A4/A3 promoter element) driving 
luciferase (233), approximately 12-fold activation of luciferase activity is observed. No  
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Figure 8. Transcription augmentation by Set7/9 is dependent upon Pdx1 residue 
K131. NIH3T3 were transiently co-transfected with Set7/9, wild-type (WT) and mutant 
Pdx1 proteins, and either Pdx1 reporter plasmid or Gal4 reporter plasmid. Cells were 
harvested 48 hours later and whole cell extracts were used to assay luciferase activity. 
(A) Luciferase activities (relative to control transfections without Pdx1) with the Pdx1 
reporter plasmid, which contains tandem elements of the Ins E2/A3/A4 element 
(schematic diagram of reporter shown at the top). N=3 transfections in triplicate, *P<0.05 
for the comparisons shown; (B) Luciferase activities (relative to control transfections 
without Pdx1) with the Gal4 reporter plasmid, which contains tandem elements of the 
yeast Gal4 DNA binding domain (schematic diagram of reporter shown at the top).  N=3 
transfections in triplicate; (C) Immunoblots (for the indicated proteins) from whole cell 
extract from transfected cells. Results are representative of N=3 transfections; (D) 
NIH3T3 cells were transfected with FLAG-Set7/9 and the indicated Pdx1 proteins, then 
nuclear extracts were subjected to immunoprecipitation using FLAG antibody, the 
immunoblotted using Pdx1 antibody. Results are representative of N=2 experiments. 
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activation is observed, however, upon co-transfection of the reporter with a cDNA 
encoding Set7/9 alone (Fig. 8A). When cDNAs encoding both wild-type Pdx1 and Set7/9 
are co-transfected, a more-than-additive 18-fold activation of the reporter is observed.  
Whereas mutation of residue K123 to Arg (K123R) had no effect on reporter gene 
transactivation, mutation of K131 to Arg (K131R) or the double mutation K123R+K131R 
resulted in loss of transcriptional augmentation by Set7/9 (Fig. 8A). These effects were 
specific for the Pdx1 reporter, since no significant effects were observed on the control 
Gal4 reporter (which contains 5 tandem copies of the yeast Gal4 recognition sequence) 
(Fig. 8B). Additionally, the effects of the K131R mutation was not caused by changes in 
Pdx1 levels, since all transfected Pdx1 mutants showed similar intensity on immunoblot 
analysis (Fig. 8C). These results suggest that although both K123 and K131 appear to 
be targets for methylation by Set7/9 in vitro (with the former being preferred), only K131 
appears to be required for the transcriptional augmentation of reporter activity in cells.   
Lys methylation has been shown to affect multiple aspects of transcription factor activity, 
including protein half-life and DNA binding affinity ((241,243)). We suspected that effects 
of the K131R mutation on Pdx1 half-life were negligible, since proteins levels of the 
transfected proteins were identical for wild-type and mutants (Fig. 8C). To test if loss of 
transcriptional augmentation activity between Pdx1 K131R and Set7/9 was due to 
decreased interaction between the two proteins, a co-immunoprecipitation assay for 
Set7/9 and Pdx1 using NIH3T3 cells transfected with wild-type or mutant Pdx1 and 
Set7/9 was performed (Fig 8D). Neither the K131R mutant nor the K123+K131R double 
mutant exhibited any differences in their interaction with Set7/9, suggesting that 
interaction between Pdx1 and Set7/9 is independent of the target Lys residue being 
methylated.  
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Figure 9. Point mutations do not affect DNA binding by Pdx1. (A) NIH3T3 cells were 
co-transfected with the wild-type (WT) or mutant Pdx1 proteins, with or without 
cotransfection of Set7/9. Nuclear extracts from transfected cells were harvested and 
subjected to EMSA using 32P-labeled E-A DNA fragment containing a Pdx1 binding site 
derived from the Ins E2/A3/A4. The positions of the Pdx1-containing complex and the 
unbound, free probe (FP) are indicated by the arrows. The bottom panel shows 
immunoblots for Pdx1 and GAPDH from the same nuclear extracts used for the EMSA; 
(B) Quantitation and modeling of EMSA reactions (as in A), with increasing 
concentrations of unlabeled E-A probe. For each Pdx1 mutant, the control condition is 
the fraction of total probe bound in the absence of competitor. The ordinate represents 
probe binding (at the given competitor concentration) as a percent of the control 
condition. The apparent dissociation constants of the WT and mutant proteins are shown 
in the inset, with no statistical differences seen. Data shown are from N=3 EMSA 
experiments.  
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To ascertain the effects of the Pdx1 mutations on DNA binding affinity, we next 
performed electrophoretic mobility shift assays (EMSAs). Nuclear extracts from NIH3T3 
cells transfected with Pdx1 proteins and Set7/9 were subjected to EMSA with 32P- 
labeled rat Ins1 promoter E-A element (233,244). No apparent differences in the 
intensity of the Pdx1-specific complex were observed in the EMSAs (Fig. 9A). To 
quantify more precisely whether subtle differences in binding affinity exist, we performed 
competition EMSAs using increasing concentrations of unlabeled E-A probe. Binding 
competition curves were subsequently calculated and modeled based on single-phase 
exponential dissociation (Fig. 9B). As shown in the Fig. 9B, none of the mutants 
exhibited dissociation constants that were different from the wild-type Pdx1 protein. 
Taken together, the data in Figs. 8 and 9 suggest that the transcriptional augmentation 
by Set7/9 that is enabled by methylation at K131 likely involves transcriptional events 
that occur post binding to DNA, such as through the activation of the RNA polymerase II 
complex at the promoter (235). 
C. Residue K131 of Pdx1 is methylated in cells 
 We next asked if Pdx1 residue K131 is methylated by Set7/9 in cells. To assess 
methylation in cells, we generated a peptide-based polyclonal antibody against 
methylated K131 of Pdx1. Three different peptides (two methylated and one 
unmethylated at Lys residues) corresponding to the Pdx1 sequence containing K131 
were subjected to dot blots using varying dilutions of the antibody. As shown in Fig. 10A, 
the antibody exhibited specificity for the Lys-methylated peptides (Fig. 10A).  
Corresponding specificity of the antibody for methylated full-length Pdx1 was observed 
using recombinant Pdx1 proteins methylated by Set7/9 in vitro (Fig. 10B): as expected, 
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almost complete loss of immunoreactivity was observed with the K131R mutation. 
However, some cross reactivity of the antibody was observed with methylated K123, 
since the K123R mutation showed a slight reduction in immunoreactivity (Fig. 10B).  
These data confirm that K131 is a site for methylation by Set7/9 in vitro. This antibody 
was then used to assess the methylation of Pdx1 proteins immunoprecipitated from 
cells. Wild-type and mutant Pdx1 constructs containing an N-terminal hemagglutinin 
(HA) tag were transfected along with Set7/9 into HEK293 cells, which contain no 
endogenous Pdx1. Pdx1 proteins were immunoprecipitated using an anti-HA antibody, 
then subjected to immunoblotting using the anti-Pdx1(K131-Me) antibody. As shown in 
Fig. 10C (lane 2), wild-type Pdx1 was methylated in cells, and the K131R and 
K123R/K131R double mutants showed clear reduction in methylation. A slight reduction 
in the K123R mutant is consistent with cross-reactivity of the antibody for methylated 
K123. Taken together, these data suggest that K131 (and possibly K123) are methylated 
in cell lines. 
To determine if K131 is endogenously methylated in β cells, we 
immunoprecipitated methylated-Lys proteins from INS-1(832/13) insulinoma cells, then 
subjected the immunoprecipitate to immunoblotting using an anti-Pdx1 antibody. Initial 
experiments from INS-1 cells revealed no recovery of methylated Pdx1, raising the 
concern that β cells may contain demethylases that diminish the ability to detect Pdx1 
methylation. To circumvent this possibility, we pretreated INS-1 cells with the Lys 
demethylase inhibitor BP-107-7 (Fig. 10D, top panel). INS-1 cells pretreated with 10 µM 
BP-107-7 overnight were subjected to immunoprecipitation using anti-Pdx1 antibody and 
the resulting immunoprecipitate was immunoblotted with anti-methylated Lys antibody.   
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Figure 10. Residue K131 of Pdx1 is methylated in cells. (A) Dot blot analysis using 
two dilutions of anti-Pdx1(K131-Me) antibodies and methylated and unmethylated 
peptides corresponding to the N-terminus of Pdx1 containing residue K131; (B) 
Representative immunoblots (top panels) using anti-Pdx1(K131-Me) antibody or anti-
Pdx1 antibody on recombinant Pdx1 proteins methylated by Set7/9 in vitro. Quantitation 
of immunoblots (N=3) is shown in the bottom panel bar graph. *P<0.05 compared to 
Pdx1 alone; (C) HEK293 cells were transfected with Set7/9 and wild-type (WT) or 
mutant HA-tagged Pdx1 proteins, then whole-cell extracted were immunoprecipitated 
using anti-HA antibody, followed by immunoblot analysis using anti-Pdx1 and anti-
Pdx1(K131-Me) antibodies (top panels). Quantification of methylated Pdx1 (relative to 
total immunoprecipitated Pdx1) (N=3) is shown in the bottom panel bar graph. *P<0.05 
compared to WT Pdx1; (D) Top: chemical structure of the Lys demethylase inhibitor BP-
107-7 (top). Bottom: INS-1 832/13 β cells were treated with vehicle or BP-107-7 (10 µM) 
overnight, then nuclear extracts were immunoprecipitated using anti-methyl Lys antibody 
followed by immunoblot using anti-Pdx1 antibody.  
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As shown in Fig. 10D (lower panel), whereas INS-1 cells treated with vehicle 
showed no recovery of methylated Pdx1, cells treated with BP-107-7 showed a clear 
signal for Pdx1. These data suggest that Pdx1 is endogenously methylated and 
demethylated in β cells. To verify methylation at residue K131 in β cell lines, TAP-tagged 
Pdx1 was overexpressed in MIN6 β cells using adenoviral gene transfer. The tagged 
Pdx1 protein was then purified from MIN6 β cells and analyzed by LC/MS/MS. Pdx1 was 
found to be both di- or tri-methylated at residue K131 (Fig. 7C shows data for the tri-
methylated protein). Collectively, these data suggest that K131 is a target of methylation 
in cells.  
D. Set7/9 is required for the maintenance of normal β cell function and glucose 
homeostasis in vivo 
In prior studies, our group showed that transient knockdown of Set7/9 in islet β 
cells results in a reduction in several gene targets of Pdx1 (245), yet the link between 
Set7/9 and β cell function in vivo has not been explored. To address this link more 
directly, we generated mice in which Cre recombinase recognition (Loxp) sites flanked 
exon 2 of the gene encoding Set7/9 (Setd7), such that conditional excision of the exon 
by Cre recombinase would result in a frame-shift and premature termination of the 
mRNA (Fig. 11A). This strategy ensures deletion of both the putative Pdx-1 interaction 
domain (at the N-terminus) and the methyltransferase domain (the SET domain) at the 
C-terminus. Setd7Loxp/+ mice were crossed to mice that express the Cre transgene 
exclusively in islet β cells when treated with tamoxifen (MIP1-CreERT, ref. (246)).  
Setd7Loxp/Loxp;MIP1-CreERT mice and littermate controls (Setd7+/+;MIP1-CreERT and 
Setd7Loxp/Loxp) were treated with 5 daily doses of tamoxifen at 8 weeks of age to generate 
β cell-specific Set7/9 knockout mice (Set∆β) and controls, respectively. At 12 weeks of  
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Figure 11. β cell-specific deletion of Set7/9 in mice. (A) Schematic representation of 
WT and mutant alleles present in control and mutant mice, respectively, showing 
positions of the exons (numbered) and the Loxp sites; (B) Immunoblot analysis of whole 
cell lysates of islets isolated from Setd7+/+;MIP1-CreERT (MIP1-Cre), Setd7Loxp/Loxp 
(Lox/Lox), and MIP1-CreERT;Setd7Loxp/Loxp (SetΔβ) mice for Set7/9 (upper panel) and 
GAPDH (lower panel); (C) Results of intraperitoneal GTT on MIP1-Cre (N=12), Lox/Lox 
(N=9) and SetΔβ (N=12) mice (left panel), with corresponding area under the curve 
(AUC) analysis (right panel). *P<0.05 compared to either MIP1-Cre or Lox/Lox; (D) 
Results of glucose-stimulated insulin release assays from islets isolated from MIP1-Cre, 
Lox/Lox, and Set∆β mice (left panel), and corresponding ratio of insulin secreted at high 
glucose relative to low glucose is shown in the right panel. N=3, *P<0.05 compared to 
either MIP1-Cre or Lox/Lox; (E) Results of real-time RT-PCR for the indicated genes 
from islets isolated from control (MIP1-Cre and Lox/Lox) vs. Set∆β mice. Data are 
normalized to Actb mRNA levels, N=4 independent islet isolations, *P<0.05 compared to 
control.  
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age (~3 weeks after conclusion of tamoxifen treatment), islets isolated from Set∆β mice 
showed a clear reduction in Set7/9 levels by immunoblot (Fig. 11B).Set∆β mice displayed 
impaired glucose tolerance following an intraperitoneal glucose challenge (Fig. 11C). To 
test the possibility that impaired glucose tolerance was caused by β cell dysfunction, we 
isolated islets from Set∆β mice and controls and performed glucose stimulated insulin 
secretion studies in vitro. As shown in Fig. 11D, islets from Set∆β mice displayed 
diminished glucose-stimulated insulin secretion compared to islets from controls, even 
when corrected for islet insulin content. These data suggest a defect in insulin secretory 
mechanisms, and is reminiscent of defects seen in Pdx1-deficient islets (247,248). Gene 
expression analysis of isolated islets revealed reductions in the mRNA levels of key 
Pdx1-regulated genes, including MafA, Slc2a2, Gck and Pdx1 itself in Set∆β islets 
compared to controls (Fig. 11E). The pre-mRNA and mRNAs encoding preproinsulin 
showed no change and a ~2-fold increase, respectively, in Set∆β islets compared to 
controls, suggesting that the response of this gene may either be delayed compared to 
the other Pdx1 targets, or that it exhibits more complex regulation in the absence of 
Set7/9. Taken together, the data from Set∆β mice suggest a role for Set7/9 in the 
maintenance of key Pdx1 target genes and overall glucose homeostasis in vivo, and 
parallels the phenotype seen with reductions in Pdx1 itself. 
E. Set7/9 plays an important role in β cell proliferation and function from the 
development. 
Since Pdx1 is crucial to pancreatic formation, it is quite likely that Set7/9 also 
plays an important role in the development and function of the β cell. Yang et al. 
demonstrated that Set7/9 localizes to the nucleus along with Pdx1 during the conversion 
of an α cell to a β cell, indicating that Set7/9 may be involved in the differentiation of a β 
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cell (78). To further elucidate the role of Set7/9 during development, we modulated the 
levels of Set7/9 using two different mouse models. We used a pancreas specific Set7/9 
deletion model, wherein the Cre recombinase expression was driven by a Pdx14.7-Cre 
promoter. Thus, Set7/9 was deleted from e9.5 specifically in the pancreas and the 
knockout mice are referred to as Set7/9Δpanc. The Set7/9Δpanc mice are significantly 
glucose intolerant, compared to their wildtype littermates (Fig 12A). In addition, 
compared to wildtype littermates, the knockout mice do not display any variations in 
insulin sensitivity (data not shown), indicating that deletion of Set7/9 could potentially 
impair β cell function. Fig 12B shows that isolated islets from Set7/9Δpanc mice show a 
dramatic reduction in Set7/9 and around a 50% reduction in Pdx1 protein levels. 
Interestingly, immunohistochemistry analysis revealed that Set7/9Δpanc mice displayed a 
reduction in Pdx1 and MafA protein levels (Fig 12C), providing a possible explanation for 
the impaired glucose tolerance that we observe in the knockout mice. As Pdx1 and MafA 
are important for the maintenance of β cell function, a deficiency in these two 
transcription factors decrease β cell function and impair glucose homeostasis. 
Set7/9Δpanc mice also had reduced β cell area (Fig 12D), which could be a consequence 
of diminished Pdx1 levels and further worsen glucose tolerance. These results suggest 
that Set7/9 may play an important role in the maintenance of β cell proliferation and 
function. The other Set7/9 mutant model used was the pancreas specific Set7/9 
transgenic mice (pSet7/9Tg), wherein the pancreas-specific expression of a Set7/9-flag 
transgene was driven by a 4.7Kb murine Pdx1 promoter (Fig 13A). Interestingly, 
pSet7/9Tg female mice showed better glucose tolerance (Fig 13B), while the males did 
not. As ERα activation has been shown to improve β cell function (249), and Set7/9 has 
been reported to increase ERα function (120), the effect of Set7/9 on β cell function 
could be gender dependent. 
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Figure 12. Pancreas-specific deletion of Set7/9 in Set7/9Δpanc mice: (A) Results of 
intraperitoneal GTT performed on 12 week old Lox/Lox (N=15) and Set7/9Δpanc (N=17) 
mice (left panel), with corresponding area under the curve (AUC) analysis (right panel). 
*P<0.05 compared to wildtype littermate controls; (B) Immunoblot analysis of whole cell 
lysates of islets isolated from 20 week old Setd7Loxp/Loxp (Lox/Lox), and Set7/9Δpanc mice 
for Set7/9, Pdx1 and GAPDH; (C) Results of immunofluorescence analysis of pancreatic 
sections from Setd7LoxP/LoxP mice and Set7/9Δpanc mice for MafA, Glut2 and Pdx1 
counterstained with Insulin and DAPI;  (D) Results of β cell area% from 20 week old 
Setd7Loxp/Loxp and Set7/9Δpanc mice. 
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Figure 13. Pancreas-specific expression of Set7/9-FLAG transgene in mice. (A) 
Schematic representation of Set7/9 transgene expressed in the pSet7/9Tg mice, 
showing the presence of the Pdx1 promoter; (B) Results of intraperitoneal GTT on 
wildtype littermates (N=14) and pSet7/9Tg (N=10) mice (left panel), with corresponding 
area under the curve (AUC) analysis (right panel). *P<0.05 compared to control mice;  
(C) Immunoblot analysis of whole cell lysates of islets isolated from wildtype littermate 
control mice and pSet7/9Tg mice for Flag, Set7/9, Pdx1 and GAPDH 
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Although the pSet7/9Tg mice showed a mild, but significant improvement in 
glucose tolerance (Fig. 8B) expression did not alter Pdx1 protein levels (Fig 13C). 
Therefore, although Set7/9 deletion affects Pdx1 protein expression and function, Set7/9 
overexpression does not. A possible explanation for this finding is that transgenic Set7/9 
may modulate only a subset of β cell proteins, therefore enhancing glucose tolerance 
mildly. Although one of the targets of Set7/9 appears to be Pdx1, as verified by the SetΔβ 
and the Set7/9Δpanc mice, the other targets of Set7/9 in the β cell remain to be 
investigated.   
3.3. Discussion 
Pdx1 is required for both the development and function of islet β cells and, as 
such, the mechanism underlying its regulation of transcription has been the subject of 
numerous studies. Nevertheless, the full extent of the mechanisms governing Pdx1 
action remains to be elucidated. Set7/9 is a Lys methyltransferase that has been shown 
to interact with Pdx1 and augment Pdx1 action at several target genes (245). In this 
study, we provide data suggesting that Set7/9-mediated methylation of Pdx1 augments 
Pdx1 transcriptional activity. Although other studies have shown that Pdx1 can be 
regulated by phosphorylation (250–254), O-GlcNAcylation (255), and sumoylation (256), 
ours is the first study that shows that Pdx1 can be methylated.  Moreover, we show the 
close linkage between Pdx1 and Set7/9 in vivo, where the loss of Set7/9 in β cells 
closely parallels the phenotype seen with reduction in Pdx1 levels. 
In recent years, the number of identified non-histone targets of Set7/9 
methylation has been increasing. Depending upon the protein, Lys methylation appears 
to affect a variety of functions, including protein-protein interactions, protein stability, and 
DNA binding affinity (241,243). Notable proteins that are substrates of Set7/9 Lys 
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methylation include p53 (236), estrogen receptor-α (238), nuclear factor κB 
(237,239,257), and TATA box binding protein-associated factor 10 (258), among others. 
In this study, we show evidence that Pdx1 is methylated at Lys residues in vitro and in β 
cells. An important finding in vitro was that recombinant Pdx1 was methylated by Set7/9, 
but occurred only in the context of the full length protein. This requirement for context-
dependent methylation seemingly differs from those reported in the literature, where 
Set7/9 has been shown to methylate Lys residues of specific small peptides, whose 
sequences could be subsequently used to predict the corresponding full-length protein 
targets (242,259). To our knowledge, none of the small peptide sequences presented in 
those studies correspond to sequences in Pdx1. As such, our studies emphasize that 
targets of Set7/9 and possibly other SET domain-containing methyltransferases may not 
be predictable based on peptide sequence specificity. More detailed structural studies 
will be necessary to identify how specific secondary and tertiary structural folds of Pdx1 
allow for its methylation by Set7/9. 
Our mass spectrometric and mutational analyses in vitro demonstrate that Pdx1 
is methylated at two Lys residues in the N-terminal transactivation domain, K123 and 
K131, with K123 being the apparent preferential target for Set7/9 in vitro. Interestingly, 
K131 seems to be the more relevant target of methylation when Pdx1 is expressed in 
cells, and suggests K131 methylation has greater functional consequences in the 
context of the cellular milieu. Our finding that Pdx1 methylation becomes more apparent 
when cells are treated with Lys demethylase inhibitors suggests also that methylation 
may be transient in cells, or perhaps regulated depending upon the target gene or 
functions of Pdx1. In this regard, there are several reports that show that proteins 
methylated by Set7/9 are reciprocally regulated by the demethylase LSD-1 (260–263).  
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Whereas methylation of Pdx1 by Set7/9 in vitro resulted in mono-methylation of 
K131 (and K123), our overexpression studies in β cells showed that K131 was di- and 
tri-methylated. This observation raises an important issue that has been discussed in the 
literature on the stoichiometry of Lys methylation by Set7/9. Some studies have 
suggested that Set7/9 functions as a di-methyltransferase (264), whereas others 
suggest it is exclusively a mono-methyltransferase (265). These seemingly contradictory 
observations could be explained by at least three possibilities: (a) mono- vs. di-
methylation could be sequence-dependent. In this respect, studies have shown that 
some peptide sequences are di-methylated by Set7/9 in vitro, whereas other peptide 
sequences are mono-methylated (242); (b) in β cells, interacting proteins may alter the 
nature of Lys methylation by Set7/9. For example, the methyltransferase G9a exhibits 
differing stoichiometries of methylation in vivo depending the presence of interacting 
proteins (266); and (c) Set7/9 may be the first in a cascade of different 
methyltransferases that achieves di- and tri-methylation of Pdx1 residue K131 in cells.   
Set7/9 has been previously shown to augment Pdx1 transcriptional activity in 
reporter gene assays (235). Here, we observed that Pdx1 residue K131 is necessary for 
this augmentation, since mutation of this residue to Arg (K131R) abrogates 
transcriptional augmentation. Although the transcriptional augmentation by Set7/9 is only 
about 40%, the effects of such reductions may have biologically significant 
consequences in the longer term. We next probed possible reasons for how the K131R 
mutation abrogates transcriptional augmentation by Set7/9. We found that mutation did 
not hamper Pdx1-Set7/9 interactions (as determined by co-immunoprecipitation 
experiments) or DNA binding affinity (based on EMSA analysis). However, It remains 
possible that binding to target genes in the nucleus may be subtly altered by the 
mutations. Nevertheless, based on our data, we believe that Pdx1 methylation at K131 
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may affect the interactions of the Pdx1 transcriptional complex with basal transcriptional 
machinery. In support of this possibility, we previously showed that Pdx1-Set7/9 
interaction was associated with activation of RNA polymerase II (235,267).  
Finally, to interrogate the relationship between Set7/9 and Pdx1 target genes in β 
cells in vivo, we generated mice with tamoxifen-inducible β cell-specific deletion of 
Set7/9 (Set∆β). Similar to mice with haploinsufficiency of Pdx1, Set∆β mice exhibited 
glucose intolerance and β cell dysfunction (247). Several Pdx1 target genes were 
reduced in Set∆β mice, consistent with the close functional linkage between Set7/9 and 
Pdx1. Our results are similar to those we previously published using RNA interference to 
deplete Set7/9 acutely in islets (245). Although these studies do not definitively prove a 
link between Set7/9 and methylated Pdx1 (since the loss of Set7/9 may have 
consequences on broader gene expression), these results do suggest that Pdx1 may be 
dependent upon the action of Set7/9 for full activity in vivo.   
Taken together, our data suggest a previously unappreciated posttranslational 
modification of Pdx1 that appears to affect its transcriptional activity. Our studies show 
the methylation of Pdx1 residue K131, the requirement of K131 for the augmentation of 
gene transcription in reporter assays, the occurrence of K131 methylation in β cell lines, 
and the requirement for Set7/9 in the maintenance of at least a subset of Pdx1 target 
genes in vivo. Some limitations and alternative interpretations of our study must be 
acknowledged. Most notably, it remains possible that the effects observed in our reporter 
assays or in Set∆β mice are not directly related to methylation of Pdx1 per se, but rather 
to a separate requirement for residue K131 or Set7/9, respectively, on gene 
transcription. Gene knock-in studies in mice (using the K131R mutation of Pdx1) may be 
more appropriate to address this issue in the future. Also, our studies do not exclude the 
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possibility in vivo that Set7/9 is directly necessary for the maintenance of chromatin 
structure (histone methylation) at several of the Pdx1 target genes examined, or that it 
acts in concert with β cell transcription factors other than Pdx1. Nevertheless, our 
studies provide a framework for understanding better the nuances of transcriptional 
regulation by Pdx1. We propose a model in which Pdx1 methylation at residue K131 via 
Set7/9 is required for the maintenance of transcription at selected target genes.  
However this model does not exclude the possibility (as reported in prior studies) that 
histone methylation by Set7/9 also contributes to transcriptional activity, this model 
emphasizes that transcription factor-cofactor interactions can achieve functional 
transcriptional complexes in many ways.  
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CHAPTER 4: PPAR-γ Activation Reduces Islet β Cell Stress and β Cell Death in 
Pre-Type 1 Diabetic Female NOD Mice 
 
 In this chapter, I investigate the contribution of β cell survival and function to 
autoimmune diabetes. To figure out the effect of the β cell in the pathogenesis of type 1 
diabetes, prediabetic NOD mice were treated with a PPARγ agonist, known to improve β 
cell health and function and the mice were assessed for glucose homeostasis and 
autoimmune response.  
 
4.1 Introduction 
Type 1 diabetes (T1D) is characterized by the loss of insulin production, as β 
cells succumb to targeted autoimmunity. The non-obese diabetic (NOD) mouse 
spontaneously develops T1D and is used as a model that closely mimics human disease 
(178). In this model, infiltration of the islet by cells of the immune system (insulitis) is 
observed as early as 4 weeks of age, with the subsequent development of diabetes in 
many animals by 12-20 weeks of age (268). The concept that the only defect in T1D lies 
in the immune system has been challenged in recent years. In recent studies, our group 
demonstrated that endoplasmic reticulum (ER) stress and resultant insulin secretory 
defects in the β cell precede the onset of T1D in mice (196). These findings raise the 
intriguing possibility that ER stress in the β cell might contribute to the aberrant 
production of “neoantigens” that subsequently invites insulitis (199,269). Dysfunction of 
the β cell in pre-T1D has been observed in other studies in NOD mice (270) and both β 
cell ER stress and dysfunction has been observed in humans with early T1D or destined 
to develop T1D (190,194). Therefore, therapies that directly target β dysfunction and ER 
stress may prove useful as adjunctive therapies to delay/prevent T1D.  
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Thiazolidinediones (TZDs) are activators of the nuclear transcription factor 
peroxisome proliferator-activated receptor-γ (PPAR-γ) and have been traditionally 
viewed as insulin sensitizers, owing to their effects on adipose tissue. However, studies 
in both humans with type 2 diabetes (T2D) and rodent models of T2D suggest that TZDs 
may also directly enhance β cell function (271,272). The mechanisms underlying the 
direct effects of TZDs on the β cell include amelioration of ER stress through reduction of 
oxidative stress (273), restoration of the sarcoplasmic-endoplasmic reticulum calcium 
ATPase 2 (SERCA2) levels (173), and restoration of levels of the β cell transcription 
factor Pdx1 and its cofactor Set7/9 (172). In addition to their potential effects on β cells, 
TZDs have also been implicated in the reduction of inflammation and autoimmunity 
owing to effects on dendritic cells, macrophages, and T cells of the immune system 
(274–276) 
The potential utility of TZDs in T1D has been limited to only a few studies. In 
humans, treatment of established T1D with the TZD pioglitazone resulted in, at best, 
modest improvements in glycemic control (277–279), raising the prospect that 
intervention with the drug in the pre-diabetic phase might have greater impact. In 
accordance with this prospect, studies in the NOD mouse have shown that 
administration of the TZDs rosiglitazone and troglitazone at the time of weaning 
significantly reduced the incidence of T1D (280,281). These studies in NOD mice did not 
address the possibility that effects on the β cell conferred by TZDs may have led to 
reduced stress and improved function early in the pathogenesis of T1D. To address this 
possibility, we studied the effects of pioglitazone in the pre-diabetic phase in NOD mice. 
Our results were consistent with a β cell protective effect of pioglitazone independent of 
effects on insulin sensitivity or body fat distribution, and suggest that reductions in early 
β cell stress in NOD mice may underlie the reduction in T1D incidence caused by TZDs. 
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4.2 Results 
A. TZD therapy improves glycemic control in pre-diabetic female NOD mice.    
Pre-diabetic female NOD mice show progressively impaired glucose 
homeostasis, impaired β cell function, and increasing markers of ER stress in islets as 
they age from 6 to 10 weeks (196). To determine if thiazolidinedione therapy can 
ameliorate β cell stress and dysfunction in the pre-diabetic phase, 6 week-old female 
NOD mice were fed a standard chow diet containing pioglitazone (0.01 wt%) until 11 
weeks of age. The wt% of pioglitazone in the diet was chosen such that the average 
daily food intake that would result in the delivery of pioglitazone at 20 mg/kg body weight 
(172). Control mice were fed an identical diet not containing pioglitazone. During the 
course of the study, none of the animals developed overt diabetes (defined as blood 
glucose on consecutive occasions exceeding 250 mg/dl). Pioglitazone is known to 
increase body weight and fat mass in mouse models of T2D (172). However, over the 
course of this study, pioglitazone-treated NOD mice gained weight at rate identical to 
controls (Fig. 14A), and demonstrated no differences in body fat composition as 
determined by dual-energy x-ray absorptiometry scanning at the end of the study (Fig. 
14B, C, and D). Nevertheless, at 10 weeks of age, pioglitazone-treated mice exhibited a 
significant improvement in glycemic control compared to control mice, as judged by an 
intraperitoneal GTT and corresponding AUC analysis (Fig. 14E and F). To assess if the 
improved glycemic control in pioglitazone-treated mice was caused by altered insulin 
sensitivity, an intraperitoneal insulin tolerance test was performed, revealing no gross 
differences in insulin sensitivity between the two groups (Fig. 14G and H). To further 
determine if pioglitazone treatment affected insulin signaling, control and pioglitazone 
mice were injected with saline or insulin (10U/Kg). Liver and Muscle tissues were  
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Figure 14. Effect of pioglitazone treatment on metabolic parameters in pre-diabetic 
NOD mice. 6 week-old pre-diabetic NOD mice (n=10 per group) were placed on either 
normal chow (Control) or chow containing 0.01 wt% pioglitazone (Pio). (A), body weights 
during feeding, (B) lean body mass as assessed by dual-energy x-ray absorptiometry 
after 4 weeks of feeding, (C) fat mass as assessed by dual-energy x-ray absorptiometry 
after 4 weeks of feeding, (D) percent body fat as assessed by dual-energy x-ray 
absorptiometry after 4 weeks of feeding, (E) results of intraperitoneal GTT after 4 weeks 
of feeding, (F) AUC analysis of GTT shown in panel E, (G) results of intraperitoneal 
insulin tolerance test after 4 weeks of feeding, (H) AUC analysis of corresponding ITT in 
panel G, (I) Immunoblot analysis of liver and muscle extracts from fasted control and 
pioglitazone treated mice injected with saline or insulin (10U/Kg) using S473-phospho 
Akt antibody and Total Akt antibody.*Indicates that the value is significantly different 
from control by two-tailed t test.  
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extracted 5 minutes post injection and immunoblot assays revealed that there were no 
differences in Akt phosphorylation between control and pioglitazone treated groups, 
indicating pioglitazone treatment does not affect insulin sensitivity.  Taken together, 
these results suggest that the improvement in glucose tolerance seen with pioglitazone 
may be secondary to improvements in β cell function. 
B. TZD therapy augments insulin secretion in pre-diabetic female NOD mice 
To determine more directly if the improved glycemic control was a consequence 
of enhanced β cell function, serum insulin levels were measured following an 
intraperitoneal glucose load. As shown in Fig. 15A, pioglitazone-treated mice displayed 
significantly higher levels of serum insulin compared to the control group at 10 minutes  
following the intraperitoneal glucose load. To determine if pioglitazone treatment affected 
β cell ER stress, we next measured random-fed insulin, proinsulin, and the proinsulin: 
insulin ratio. Higher proinsulin: insulin ratios have been shown to correlate to ER stress 
in NOD mice (196). As shown in Fig. 15B-D, whereas the random-fed insulin was a 
significant 2-fold greater in the treatment group compared to controls, the proinsulin 
levels were not significantly different, resulting in a proinsulin: insulin ratio that trended 
lower (P=0.07) in the treatment group. In total, the results in Fig. 15 show that 
pioglitazone treatment causes an improvement in β cell function and a potential 
reduction in β cell ER stress.  
C. Pioglitazone treatment reduces islet ER stress  
To assess more directly the possibility that pioglitazone reduced ER stress in 
NOD mice, we next isolated islets from treated and control mice at the end of the study 
and measured both mRNA and protein markers of ER stress.  ER stress is characterized 
by activation of three distinct pathways, IRE1α, PERK, and ATF6. In islet β cells, the  
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Figure 15. Effect of pioglitazone on insulin secretion in pre-diabetic NOD mice. 6 
week-old pre-diabetic NOD mice (n=10 per group) were placed on either normal chow 
(Control) or chow containing 0.01 wt% pioglitazone (Pio). (A) serum insulin levels at the 
indicated time points following intraperitoneal glucose injection (2.0 g/kg body weight) 
after 4 weeks of feeding, (B) random-fed insulin levels after 4 weeks of feeding, (C) 
random-fed proinsulin levels after 4 weeks of feeding, (D) random-fed proinsulin:insulin 
ratio after 4 weeks of feeding. *Indicates value is significantly different compared to time 
0 (panel A) or Control (panel B) by two-tailed t test. 
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Figure 16. Effect of pioglitazone on β cell ER stress and area% in pre-diabetic NOD 
mice. 6 week-old pre-diabetic NOD mice were placed on either normal chow (Control) or 
chow containing 0.01 wt% pioglitazone (Pio). After 4 weeks of feeding, pancreas was 
harvested (n=5) or islets were isolated and subjected to RT-PCR (n=3 per group) or 
immunoblot analysis (n=2-3 per group). (A) spliced Xbp1 (sXbp1) mRNA (relative to Actb 
mRNA), (B) Atf4 mRNA (relative to Actb mRNA), (C) immunoblot analysis for Bip, Pdx1, 
GAPDH, Atf4 and Actin (D) β cell area as a percentage of total pancreas area for 
animals at the indicated ages, (E) Unmethylation index from serum of mice (n=4-5 per 
group). *Indicates that the values are significantly different for the comparisons shown 
(panel D) by one-way ANOVA or compared to Control (panels A, B, and E) by t test. 
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 IRE1α and PERK pathways predominate, and are evident by increases in spliced Xbp1 
mRNA and ATF4 protein levels, respectively (282). As shown in Fig. 16A-B, there were 
significant reductions in spliced Xbp1 (sXbp1) and Atf4 mRNA levels in islets from 
pioglitazone-treated mice compared to controls. The reduction in Atf4 mRNA was 
reflected by a reduction in the corresponding ATF4 protein level by immunoblot analysis 
(Fig. 16C). Fig. 16C also shows a reduction in the levels of the protein folding chaperone 
Bip. The reduction in islet ER stress (and possible death) with pioglitazone treatment led 
us to assess relative β cell area in treated and control mice. Fig. 16D shows that β cell 
area% is increased 2-fold upon pioglitazone treatment. The relatively greater β cell area 
in pioglitazone-treated mice resulted at least in part from reduced β cell death, as 
methylated preproinsulin DNA in serum (a biomarker of dying β cells, ref. (223)) was 
significantly reduced upon pioglitazone treatment at the end of the study (Fig. 16E).   
Prior studies have shown that Pdx1 is required for the β cell to appropriately cope 
with ER stress, as haploinsufficiency of Pdx1 reduces the β cell ER stress threshold in 
mice and increases β cell apoptosis (45). Because TZDs are known to augment Pdx1 
levels (172,175), we also measured Pdx1 protein levels in islets. However, examination 
of Pdx1 by immunofluorescence of pancreas sections and by immunoblotting of isolated 
islets revealed no effect of pioglitazone on Pdx1 levels (Fig. 16C), suggesting that the 
effect of pioglitazone in reducing β cell ER stress was independent of Pdx1 protein 
levels.  
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D. Pioglitazone treatment reduces insulitis in NOD mice but does not affect T cell 
proliferation in vitro 
Exposure of β cell antigens, a consequence of β cell ER stress/death, results in 
eventual activation of autoreactive T cells and development of insulitis (283). We 
therefore assessed insulitis in histological sections of pancreas from treated and control 
mice. Fig. 17A and B shows that pioglitazone reduced the incidence and severity of 
insulitis compared to controls. We next isolated pancreatic lymph nodes from mice and 
assessed the effect of pioglitazone treatment on CD4+ T cell populations in these 
tissues. Notably, pioglitazone had no significant effect on Th1, Th17 (CD4+IL17A+), or 
Treg (CD4+CD25+Foxp3+) cell populations in the pancreatic lymph node (Fig 4C).  
The reductions in insulitis without effects on specific CD4+ T cell populations led 
us to consider if pioglitazone might have caused a generalized reduction in T cell 
proliferation. Unfractionated splenocytes from NOD mice were loaded with the dye  
carboxyfluorescein succinimidyl ester (CFSE) and subjected to polyclonal stimulation 
using a combination of anti-CD3 antibody, anti-CD28 antibody, and IL-2 in vitro to mimic 
antigen-dependent and -independent signals as seen in T1D (284). After 4 days 
stimulation in the presence or absence of 1 or 10 µM pioglitazone, cells were gated on 
CD4+ cells and analyzed for CFSE dilution by flow cytometry. Fig 18A shows 
representative histograms demonstrating dilution of CFSE upon stimulation with anti-
CD3/anti-CD28/IL-2, a finding indicative of T cell proliferation. No differences in CFSE 
dilution were observed with either 1 µM or 10 µM pioglitazone (Fig. 18A and B), 
indicating that pioglitazone at these concentrations does not alter the proliferative rate of 
T cells. These data suggest that the reduction in insulitis seen in treated mice is not 
likely an effect of pioglitazone to directly suppress T cell proliferation.  
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Figure 17. Effect of pioglitazone on the frequency and severity of insulitis in pre-
diabetic NOD mice. 6 week-old pre-diabetic NOD mice were placed on either normal 
chow (Control) or chow containing 0.01 wt% pioglitazone (Pio). After 4 of weeks feeding, 
pancreas and pancreatic lymph nodes were harvested from animals (n=5). (A) 
representative images of islets (brown staining) from control- and pioglitazone-treated 
animals; arrows indicate infiltrating immune cells (insulitis), (B) results of insulitis scoring 
of control- and pioglitazone-treated animals, (C) flow cytometry analysis from pancreatic 
lymph nodes showing Treg cells (CD4+CD25+Foxp3+) as a percentage of total CD4+ 
cells, (D) flow cytometry analysis from pancreatic lymph nodes showing Th1 cells 
(CD4+IFN-γ+) as a percentage of total CD4+ cells, (E) flow cytometry analysis from 
pancreatic lymph nodes showing Th17 cells (CD4+IL17A+) as a percentage of total 
CD4+ cells. 
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Figure 18. Proliferation of splenocytes in response to pioglitazone treatment in 
vitro. Isolated NOD mouse splenocytes were stimulated in vitro with anti-CD3/anti-CD28 
and IL-2 for 4 days then gated on CD4+ cells by flow cytometry. (A), CFSE dye 
fluorescence intensity in unstimulated (red line) and stimulated (blue line) CD4+ cells in 
the absence of pioglitazone; (B), effects of 0 µM (blue line), 1 µM (red line), and 10 µM 
(green line) pioglitazone on CFSE fluorescence intensity in stimulated CD4+ cells, (C), 
quantitation of median CFSE fluorescence intensity from experiments in panel B from 3 
independent experiments, (D) flow cytometry analysis from 4-day stimulated splenocytes 
showing Treg cells (CD4+CD25+Foxp3+) as a percentage of total CD4+ cells, (E) flow 
cytometry analysis from 4-day stimulated splenocytes showing Th1 cells (CD4+IFN-γ+) 
as a percentage of total CD4+ cells, (F), flow cytometry analysis from 4-day stimulated 
splenocytes showing Th17 cells (CD4+IL17A+) as a percentage of total CD4+ cells. 
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E. Pioglitazone treatment reduces TXNIP mRNA and protein 
Previous studies of pioglitazone suggested that its protective effects in β cells in 
the setting of type 2 diabetes result from reductions in oxidative stress. We therefore 
examined levels of mRNA encoding anti- and pro-oxidant proteins in islets from control 
and treated mice. As shown in Fig. 19A, whereas the mRNAs encoding the antioxidant 
proteins glutathione peroxidase (Gpx1) and superoxide dismutase (Sod1) were 
unchanged upon pioglitazone treatment, the mRNA encoding pro-oxidant protein 
thioredoxin interacting protein (Txnip) was reduced more than 5-fold. Thioredoxin 
interacting protein (TXNIP) was recently shown to mediate ER stress-induced cellular 
death in islets (170,171). To interrogate in greater detail whether pioglitazone treatment 
suppresses Txnip mRNA and corresponding protein, we employed the INS-1 β cell line. 
As shown in Fig. 19B, INS-1 cells treated with the ER stress inducer thapsigargin 
displayed an increase in Txnip mRNA, whose levels were significantly reduced upon 
preincubation with 10 µM pioglitazone. Immunoblots of corresponding incubations in 
INS-1 cells revealed that TXNIP levels increased upon thapsigargin incubation and were 
also decreased by pioglitazone (Fig. 19C). Taken together, these data suggest that 
pioglitazone may promote β cell survival in pre-diabetic NOD mice through the reduction 
in TXNIP. 
4.3. Discussion 
Type 1 diabetes (T1D) develops as a disorder of the immune system in which β 
cell autoantigens, released as a result of β cell death, trigger the eventual selection and 
proliferation of autoreactive T cell clones (285). Speculation remains as to whether the 
process in which antigens are released is physiologic or pathologic. It has been 
speculated that the physiologic early turnover of β cells seen in neonatal mice (and  
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Figure 19. Effects of pioglitazone on TXNIP mRNA and protein expression. (A), 
abundance of Gpx1, Sod1, and Txnip mRNA (relative to Actb mRNA) in islets of 11 
week-old NOD mice that were fed a control (Control) and pioglitazone (Pio)-containing 
diet, (B) expression of Txnip mRNA in INS-1 cells treated with or without thapsigargin 
(Tg) in the presence or absence of pioglitazone (Pio), (C) immunoblot analysis of TXNIP 
and GAPDH from INS-1 cells treated without or without thapsigargin (Tg) in the 
presence or absence of pioglitazone (Pio). *Indicates that the value is significantly 
different from Control (panel A) or for the comparison shown (panel B). 
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possibly humans, as well) might contribute sufficient antigen exposure to trigger 
autoimmunity (286), but this possibility was recently challenged in studies of NOD mice 
(287). A second, more intriguing, hypothesis suggests that stress responses intrinsic to 
the β result in the pathologic formation of epitopes (as misfolded or postranslationally 
modified proteins) that are immunogenic (199,269). In this regard, β cell ER stress was 
recently shown to occur in the early pre-diabetic phase in NOD mice and in humans with 
new-onset T1D (194,196). Prior studies suggested potential β cell protective effects of 
TZDs (172,173,273), and because administration of TZDs to NOD mice delayed onset of 
T1D (280,281), we asked whether TZD administration might directly impact β cell 
function and survival in NOD mice.   
 Although TZDs are traditionally viewed as insulin sensitizers, evidence in recent 
years strongly suggests that they have direct effects on the β cell. These effects include 
the stimulation of Pdx1 gene activity and increases in Pdx1 protein levels in β cells 
(175), reduction in ER stress responses by stimulation of Serca2 gene activity and 
protein levels (173), and reductions in β cell oxidative stress (177,273). Moreover, TZD 
administration was shown to delay the incidence of T1D in NOD mice, although it is 
unclear if this finding was a result of β cell effects of TZDs. Based on these findings, we 
asked whether administration of the TZD pioglitazone in the pre-diabetic phase might 
protect against the early β cell dysfunction and death that contribute to later T1D. 
Notably, our studies showed that pioglitazone administration resulted in a reduction in 
islet ER stress indices, including reduced sXbp1 mRNA, reduced Atf4 mRNA and its 
corresponding protein, decreased Bip protein levels, and a trend to reduced proinsulin: 
insulin ratio. These indices correlated to enhanced insulin secretion and improved 
glucose tolerance in NOD animals treated with pioglitazone. Because our findings were 
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not accompanied by changes in body weight, body fat distribution or insulin sensitivity, 
we believe they suggest a direct effect of pioglitazone on islet β cells. 
 The mechanism by which pioglitazone reduces ER stress may be multifactorial.  
Pre-diabetic NOD mice exhibit reductions in Serca2 mRNA in islets and PPAR-γ 
stimulation has been shown to activate the Serca2 gene in β cells (173). Although we did 
not detect changes to Serca2 gene expression in our studies, it is possible that its 
activation was below our threshold of detection or that SERCA2 protein levels might 
have been enhanced independently of gene activity. Similarly, we did not observe 
changes in Pdx1 levels in β cells of pioglitazone-treated NOD mice. Pdx1 levels directly 
correlate to β cell health and to the ability of β cells to remediate ER stress; Pdx1+/- 
mice exhibit glucose intolerance and increased susceptibility to β cell ER stress (45). 
Based on our findings, we propose that the effects of pioglitazone in reducing β cell ER 
stress in NOD mice involve a molecular mechanism distinct from those previously 
suggested in the literature. 
 A notable outcome in our studies was the increased area of β cells in 
pioglitazone-treated animals compared to controls. Interestingly, β cell area was also 
higher in these animals when compared to 6 week-old NOD mice at the start of the 
study, suggesting that pioglitazone treatment either enhanced the rate of β cell 
replication or reduced β cell death- or some combination of the two. This result is 
reminiscent of studies in type 2 diabetic db/db mice, in which pioglitazone treatment 
resulted in increased β cell area that was coincident with improved glycemic control 
(172). In those studies, pioglitazone did not enhance β cell replication, but rather 
appeared to reduce cell death. In our case, pioglitazone-treated mice showed a striking 
reduction in the serum unmethylation index, a sensitive biomarker of β cell death (223).  
In light of the reduction in β cell death, it is particularly noteworthy that we observed 
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reductions in Txnip mRNA in islets of pioglitazone-treated mice with commensurate 
reductions in TXNIP levels in pioglitazone-treated INS-1 β cells. In the setting of ER 
stress, IRE1α stabilizes Txnip mRNA, whose encoded protein ultimately activates the 
Nlrp3 inflammasome and leads to β cell death (170,171). Because pioglitazone reduces 
IRE1α activity (as judged by the reduced spliced Xbp1 mRNA), we suggest that β cell 
death is reduced in NOD mice as a result of reduced TXNIP.   
 Finally, we should comment on the significant reduction in insulitis we observed 
upon pioglitazone treatment. Despite the reduction in insulitis, we did not observe 
differences in relative proportions of CD4+ T cell subtypes in the draining pancreatic 
lymph node. These findings raise the possibility that pioglitazone may have had a 
primary effect on reducing proliferation of T cells. We tested this possibility by performing 
T cell activation assays in vitro, wherein no changes in CD4+ cell proliferation or 
differentiation were observed in response to pioglitazone. Studies have shown 
stimulatory and inhibitory effects of PPAR-γ on Treg and Th17 cells, respectively 
(276,278,288), so we cannot rule out the possibility that differences in CD4+ T cell sub-
populations occurred in the immediate vicinity of the islets themselves. In the absence of 
a direct effect of pioglitazone on T cell proliferation, it nevertheless remains possible that 
the reduction in β cell death with pioglitazone may have diminished the stimulus for 
autoimmunity. 
Certain key limitations to our study must be recognized. First, notwithstanding 
some evidence to the contrary, we cannot rule out non-β cell effects of pioglitazone in 
our study, and it remains possible that β cell protective effects may still emanate from 
indirect effects on adipose tissue, muscle, or immune cells. Second, the implications of 
our findings to human T1D remain speculative. Whereas administration of TZDs delay 
onset of T1D in pre-diabetic NOD mice (280,281), their use in humans with established 
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T1D may have only modest effects on improving glycemic control (277–279). These 
results leave open the possibility that earlier intervention with pioglitazone (in the pre-
diabetic phase) may have greater impact on β cell function in humans, but such studies 
must await the development of next generation PPAR-γ activators with improved benefit-
to-risk ratio. Notwithstanding these limitations, our data support the conclusion that TZDs 
may have protective effects to reduce β cell stress and death in T1D, and also support 
the notion that an aggressive approach to β cell function represents an important 
adjunctive means to control progression or severity of T1D. 
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CHAPTER 5: Conclusions and Future Work 
 
The β cell is central to the regulation of glucose homeostasis in the body. Several 
studies have pointed to the fact that the loss of β cell function triggers the development 
of diabetes (211,289). Therefore, studying the β cell is of primary importance in tackling 
the diabetes epidemic. In this respect, I have studied the transcriptional and translational 
mechanisms underlying β cell function.  
Pdx1 is undoubtedly, the most widely studied transcription factor in the field of β 
cell biology. Pdx1 exercises control over β cell phenotype and function by regulating the 
transcription of a number of key β cell genes. A few studies have demonstrated that 
Pdx1 interacts with cofactors that regulate chromatin status and influence transcription 
(reviewed in (84)); however, regulation of Pdx1 protein itself during the process of 
transcription deserves more attention. In Chapter 3, I have shown that both recombinant 
and cellular Pdx1 protein is methylated by Set7/9, a lysine methyltransferase, at two 
lysine residues, Lys 123 and Lys 131 (Fig 6, 7 and 10) . As methylation of endogenous 
Pdx1 can be captured only when Ins1 832/13 cells are treated with a demethylase 
inhibitor (Fig 10), it is likely that Pdx1 is also regulated by demethylases. Methylation of 
Pdx1 at Lys 131 is associated with an increase in transcriptional activity, which could 
potentially be due to effects of methylation on RNA pol II. For the first time, we also 
showed that a β cell-specific Set7/9 knockout mice display significant glucose 
intolerance and impaired insulin secretion in comparison to their wildtype littermates. 
Additionally, the SetΔβ mice appear to have reductions in expression of Pdx1 and Pdx1 
target genes, demonstrating that Set7/9 regulates Pdx1 function (Fig 11). Set7/9 may of 
course, contribute to the maintenance of normal β cell function by affecting other 
proteins within the β cell. To determine if the decrease in Pdx1 target gene expression is 
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specifically due to a decrease in Pdx1 methylation, we would have to create a Lys123 
and Lys 131 mutant mouse. Another approach to delineate further the role of Pdx1 
methylation in β cell transcription, is to use β cell lines wherein endogenous Pdx1 in 
knocked down using an adenoviral-siPdx1 vector or a CRISPR/Cas9 kit and wildtype or 
mutant Pdx1 are transiently expressed, followed by assessment of Pdx1 target gene 
expression and glucose stimulated insulin secretion.  
 Interestingly, while incubation of recombinant proteins with radioactive SAM 
reveals Lys 123 to be the site of methylation (Fig. 6), immunoblot analysis of cellular 
Pdx1 using methylation specific antibodies and mass spectrometry analysis show that 
both Lys 123 and Lys 131 are methylated (Fig. 10 and 7). From the experiments 
performed in this study, Lys 131 seems to be the major target of methylation in cells that 
are transfected/ transduced with Pdx1 (Fig. 8). Although Lys 131 appears to be the more 
important target of methylation, another possibility is that we have simply not used the 
right system to investigate the function of methylation at Lys 123. Lys 123 belongs to the 
pentapeptide FPWMK, which is the site of interaction between Pdx1 and Pbx1 (88). As 
described in the introduction, the interaction between these two proteins, when 
disrupted, dramatically inhibited proliferation of all pancreatic cell types (89). Pdx1: Pbx 
interaction regulate the transcription of somatostatin (88), elastase (87), Tcf7l2 
(associated with β cell proliferation) (83), Isl1 (90) and quite possibly, many other target 
genes that still need to be investigated. Also, Pbx1 appears to be the most common 
interacting partner of Pdx1 (83). We think that, perhaps, Set7/9 mediated Lys123 
methylation can enhance Pdx1:Pbx mediated transcription, possibly through recruitment 
of other factors and enhanced stabilization of Pdx1:Pbx complex. In another study, ERα 
was shown to interact with Pbx1, which associates with increased H3K4 methylation and 
augmented transcription of ERα target genes (290), further supporting the possibility of a 
96 
 
connection between Pdx1:Pbx1 interaction and Set7/9. Interestingly, the pancreas-
specific Set7/9 knockout mice (Set7/9Δpanc) displayed worsened glucose tolerance 
coupled with reductions in Pdx1 and MafA protein and β cell proliferation. Due to the loss 
of Set7/9 and possibly reduced Pdx1 function during pancreatic development of 
Set7/9Δpanc mice, processes such as β cell proliferation, which mostly occur during 
development may get impeded. It would be interesting to determine if apart from a 
reduction in Pdx1 protein, the loss of Set7/9 affects Pdx1:Pbx interaction, which 
ultimately reduces β cell proliferation. Although there were no differences in the gross 
phenotype of the Set7/9Δpanc pancreas (size and weight), one wonders if β cells of the 
adult Set7/9Δpanc mice can compensate adequately in response to stresses such as 
streptozotocin injections or a partial pancreatectomy. As Pdx1 haploinsufficient mice 
cannot proliferate or function sufficiently in response to stresses such as a high fat diet 
(45), it is likely that Set7/9Δpanc mice or SetΔβ mice that have reduced Pdx1 levels may be 
unable to mount an adequate compensatory response to stress. Moreover, a ChIP seq 
experiment using Pdx1, Pbx1 and Set7/9 antibodies would be useful to identify all the 
common target genes and would help us to better understand the role of Set7/9 in the β 
cell. 
Normal β cell function is dictated by optimum β cell transcription and translation. 
Accumulation of unfolded protein in the ER results in ER stress and activation of the 
UPR. Unresolved ER stress results in the apoptosis of the cell. Recent reports suggest 
that early inflammatory conditions cause ER stress, which in turn, causes β cell death 
and a subsequent increase in recruitment of macrophages and other immune cells, 
thereby, assisting in its own death (195,196,198,199). Hence, although the immune 
system was thought to be the main cause for type 1 diabetes, these studies now suggest 
that the β cell may assist in its own death. In Chapter 4, we tried to address this issue by 
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asking if an improvement in β cell function and a reduction in β cell death would 
decrease insulitis. We treated prediabetic 6 week old NOD mice with pioglitazone, a 
PPARγ activator, for 4-5 weeks and then assessed islet function. We observed that 
pioglitazone treated NOD mice showed a significantly improved glucose tolerance, which 
was due to a dramatic increase in insulin secretion. Pioglitazone NOD mice displayed an 
increase in β cell area, accompanied by a significant decrease in β cell death indicating 
that pioglitazone treatment enhanced β cell survival. Treated mice also exhibited a 
decrease in the frequency and extent of insulitis, with no alterations in the size or 
proliferative capacity of Th1, Th17 and Treg cell populations, indicating that a decrease in 
β cell death could potentially prevent islet infiltration of immune cells. We then sought the 
underlying reason for lesser β cell death and found that there was a reduction in ER 
stress markers sXbp1 mRNA, Bip and ATF4 protein in islets isolated from pioglitazone 
treated mice. In addition, pioglitazone diminished Txnip mRNA expression, suggesting 
reduced ER stress mediated TXNIP expression and a potential reduction in subsequent 
IL-1β maturation contributed to decreased β cell death. This study adds to the growing 
body of evidence, further supporting the hypothesis that β cell ER stress contributes to 
inflammation and exacerbates β cell death. While the effects of pioglitazone treatment 
on the prediabetic β cell seem promising, we accept that there are certain limitations to 
the interpretation of this study. As pioglitazone is popularly used as an insulin sensitizing 
agent, we cannot rule out the effect of pioglitazone on other organs. Further experiments 
should be conducted to determine if pioglitazone affects the proliferation, maturation and 
antigen presentation ability of macrophage and dendritic cells.   
It would be interesting to know if there is an age-dependent decrease in β cell 
PPARγ expression levels or alterations in phosphorylated PPARγ levels in NOD mice, 
due to which pioglitazone administration provides a protective response. The exact 
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mechanism of pioglitazone mediated inhibition of ER stress in the β cell requires further 
investigation. Rat β cells that have mild ER stress and are exposed to cytokines show 
higher NF-κB activation, in part due to transcriptional activation by spliced Xbp1 protein 
(156). PPARγ has been reported to modulate the activity of NF-κB in several reports, 
including inhibition of NF-κB transcription, increase in IκB transcription and enhanced 
proteasomal degradation of NF-κB (291,292). In addition, PPARγ expression has been 
reported to counteract the expression of Chop and subsequently inhibit ER stress 
mediated activation of NF-κB and synthesis of IL-8, ultimately reducing inflammation in 
human intestinal epithelial cells (293). NF-κB expression is correlated with the an 
increase in β cell death (294) and development of immune mediated diabetes (295), 
therefore, PPARγ could mediate a reduction in ER stress associated cell death through 
decreased transcription of NF-κB or reduced protein stability. Furthermore, PPARγ has 
been shown to bind to the Txnip promoter and repress Txnip expression in renal cells 
(296). In β cells, PPARγ agonism could potentially repress Txnip expression in a similar 
manner or may facilitate degradation of miRNA regulating Txnip mRNA during ER stress 
(170). PPARγ can also indirectly contribute to decreased Txnip protein levels by 
ameliorating ER stress.  
As β cell dysfunction is central to the pathogenesis of diabetes, it is important to 
understand mechanisms regulating β cell function and survival. Elucidation of the 
transcriptional and translational mechanisms underlying β cell function could potentially 
provide a number of molecular targets for therapy. Hence, therapies aimed at enhancing 
the intrinsic function of transcription factors such as Pdx1 and PPARγ or influencing the 
function of Pdx1/PPARγ regulatory factors (e.g. demethylases) could improve β cell 
function. Therapies aimed at translational mechanisms of the β cell that could result in 
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resolution of ER stress have the potential to improve β cell function and survival, 
ameliorate glucose control and prevent diabetes.   
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